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Allosteric signalling was first discovered over 50 years ago, yet the underly-
ing molecular determinants are not yet completely understood. The ability
to predict the activity of allosteric small molecules could have a huge ther-
apeutic impact, as targeting allosteric sites in proteins potentially presents
significant benefits over active site inhibitors, in both selectivity and efficacy.
While some systems undergo fairly well understood structural changes,
there is no overall model that satisfactorily describes how allostery works.
Molecular dynamics (MD) simulations provide a tool to study protein dy-
namics at the atomistic level, however traditionally employed analysis meth-
ods have proven inadequate to deliver a mechanistic description of allostery,
which can be applied broadly to a range of allosteric systems.
This thesis presents the development of a Python workflow for the anal-
ysis of Molecular Dynamics (MD) simulations of proteins subjected to al-
losteric regulation. The end goal is to provide a new tool for structure-based
drug design (SBDD) for these systems. This tool computes various descrip-
tors, such as distances, torsions, collective motions and interaction ener-
gies, and then utilises two concepts from information theory to compare
these descriptors: Kullback-Leibler (KL) divergence and Mutual Informa-
tion (MI). MI is used to determine correlation between simulation descrip-
tors that can aid explanation of conformation/activity relationships; while
KL divergence is used to highlight differences of one descriptor between
simulations of related molecular systems.
Proof of concept for this approach utilises the protein phosphoinosi-
tide dependent kinase-1 (PDK1) as a test case. This protein plays a cru-
cial role in cell signalling, by activation of other kinases within the same
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family (AGC kinases). Inhibition of PDK1 has been of much interest, as
over-expression and dysfunction is related to several diseases, most notably
cancer. Active site compounds suffer from selectivity issues, as the active
site is well conserved across all AGC kinases, however PDK1 has a well
defined allosteric site, with known peptide and small molecule activators
and inhibitors. Therefore understanding this mechanism could facilitate de-
sign of more selective allosteric drugs. Long MD trajectories were run for
PDK1 in complex with three different drug like molecules for which crystal-
lographic data was available: two activators, and one inhibitor. In order to
mimic experimental assay conditions, simulation systems were composed
of PDK1, the covalently bound allosteric small molecule, ATP, two Mg2+
ions, a model of a substrate peptide, and a box of explicitly modelled water
molecules. Simulations were performed with the software Sire/OpenMM
Molecular Dynamics (SOMD). From the resulting trajectories, the KL anal-
ysis workflow was able to identify conformational differences between the
activated and inhibited systems, and identify the dominant motions lead-
ing to these structural changes. Subsequently, an energetic comparison was
performed using a per-residue decomposition of the non-bonded interac-
tions between different components of the system (protein, ligand, ATP and
substrate). Calculating MI of these energies relative to structural features
highlighted that the motion of the activation loop in PDK1 is highly cor-
related with the interaction energy of ATP with the protein only when an
allosteric ligand is bound. Further evidence to support this observation was
obtained using an extended set of 21 further compounds for which activ-
ity data was available, which share the same scaffolds as the two activators
initially studied. This confirms there is a unique conformation of the acti-
vation loop achieved only by the highest activating compounds, and not by
the inhibited complex, and that this is correlated with the interactions of the
protein with ATP.
To extend the applicability of this methodology, our attention shifted to
the more challenging test case posed by protein-tyrosine phosphatase 1B
(PTP1B). PTP1B is a promising target for the treatment of obesity and di-
abetes, as mice with deletion of the PTPN1 gene (which encodes PTP1B)
vii
show significant resistance to both conditions. As with PDK1, the active
site of protein tyrosine kinases is well conserved, and so selective phospho-
tyrosine analogue inhibitors, which bind at the active site, are difficult to
develop. In this case, exploration of the key conformational changes re-
quired the use of enhanced sampling techniques, as these processes occur on
millisecond timescales, and therefore cannot easily be sampled using equi-
librium MD. In particular, steered-MD simulations were needed to probe
the movements of the “WPD” loop, which closes over the substrate dur-
ing the catalytic cycle, and positions key residues to interact with the sub-
strate. The allosteric inhibitors for this system are believed to stabilise the
"open" loop conformation, and restrict the loop closing into the active con-
formation. Therefore understanding how this stabilisation occurs is crucial
in order to design more effective inhibitors. From the initial steered-MD
run, a “swarm of trajectories” approach was applied, seeding hundreds
of equilibrium MD runs from intermediate structures gathered during the
steered-MD. This was used to generate a Markov State Model description of
the conformational changes involved, in order to compare the loop closing
mechanism for the inhibitor-bound, and substrate-bound simulations. This
generates intermediate states of the loop closing, where KL can highlight
structural differences between the states.
Overall, this work provides a generally applicable toolkit for the anal-
ysis of equilibrium and biased MD simulations to predict and characterise




The work in this thesis describes the development of computational meth-
ods to analyse simulations of proteins, with a view to understanding how a
particular biological process known as allostery works in order to utilise it
for drug design.
In general the goal of drug design is to identify a particular biomolecule,
usually a protein or enzyme, which is involved in a disease pathway, and
design a molecule which can bind to the surface of the biomolecule, and in
doing so change its behaviour. Such a molecule is referred to as a ligand.
This is a desirable effect if a biomolecule is malfunctioning, or can have
some knock on effect to another biological system, where altering the func-
tion will have some therapeutic effect. Usually this is achieved by designing
a ligand which binds to the "active site", the region of the protein that is re-
sponsible for the function, usually the site of catalysis for an enzyme, and by
binding a ligand there, the normal process is directly blocked. However it is
also possible to bind to a region located away from the active site, and as this
binding affects the conformation and dynamical behaviour of the protein as
a whole, it is possible to alter the function at the active site, even though
the ligand is bound to a different region of the protein. This distant effect is
known as allostery, and it is an important mechanism in normal cell regu-
lation and proliferation, as it is used as a signalling mechanism. Designing
drugs that work in this way has many benefits in selectivity and efficacy
over active site ligands, but the process is not well enough understood to
make routine design of these molecules simple.
We can study this process using Molecular Dynamics (MD) simulations;
a technique which uses Newton’s classical equations of motion to simulate
the motions of atoms and molecules. By simulating a protein without any
allosteric ligand bound, and then again with different allosteric ligands, we
vi
can compare the motions between the non-ligand-bound, and ligand-bound
simulations, to highlight the effects that the allosteric ligand causes. To do
this we use different mathematical and statistical techniques to analyse the
data we obtain from the MD simulation. The first technique is known as
PCA (Principal component analysis) which reduces the complexity of look-
ing at the motions of thousands of atoms, by implementing a linear combi-
nation of these motions into a fewer number of "collective motions", where
these new motions still represent the majority of the variability in the data.
This allows us to highlight the largest collective motions (highest variance)
of the protein, and in many cases these large scale motions are of biological
significance.
We can also then look at other structural differences such as torsional
angles, interaction energies, or distances within the protein. From our MD
simulation we have many snapshots of the system, so we can make many
of each of these measurements as the protein moves. From these measure-
ments we can make distributions, and then compare the distributions from
the different simulations using a concept called the Kullback-Leibler diver-
gence, which comes from a branch of mathematics known as Information
Theory. This tells us how different a particular measurement is between
the "protein only" simulation, and the simulation with the protein plus the
allosteric ligand.
Finally, we can then use another concept from Information Theory known
as Mutual Information, to tell us how correlated two variables are. This al-
lows us to determine whether regions in different areas of the protein show
correlated motions, or whether motions correlate with interaction energies
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The term "allostery" was first presented in work by Jacques Monod in 1961
[1, 2], to describe proteins which have more than one ligand binding site,
and where binding at one site results in a change in activity at the other.
"These proteins are assumed to possess two, or at least two, stereospecif-
ically different, non-overlapping receptor sites. One of these, the actice
site, binds the substrate and is responsible for the biological activity
of the protein. The other, or allosteric site, is complementary to the
structure of another metabolite, the allosteric effector, which it binds
specifically and reversibly." [2]
Figure 1.1 summarises the two initial models presented to describe al-
lostery: the Monod-Wyman-Changeux (MWC) model [3] and the Koshland-
Némethy-Filmer (KNF) model [4]. For a multimeric system, binding of a
ligand to one subunit can affect the ligand binding affinity of another sub-
unit. The MWC model describes this cooperativity with a two state model,
where binding of a ligand to one subunit shifts the equilibrium of these two
states, and this is the explanation for the cooperativity seen. The KNF model
on the other hand considers ligand binding steps to be sequential: in that
binding of a ligand to one subunit instigates a conformational change in
that subunit, which affects neighbouring subunit conformations and affects
their binding affinity.
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FIGURE 1.1: The MWC model of protein allostery which de-
scribes two states, termed as tense (purple) or relaxed (ma-
genta), either of which can be stabilised by allosteric binding
of a ligand (green).
These two, and other early models, based their descriptions on the study
of hemoglobin, where cooperativity between the 4 subunits that form the
quaternary complex is essential for function. This phenomenon was known
for some time before the concept of allostery was developed, as studies by
Christian Bohr in 1904 [5] found that after the first molecule of oxygen binds,
the subsequent binding to the three remaining subunits occurs more read-
ily. This cooperativity can be seen by noting that the binding affinity does
not increase linearly with ligand concentration, and this can be either posi-
tive or negative; where initial binding promotes further binding, or restricts
further binding. This effect is allostery: binding of one oxygen molecule the
hemoglobin tetramer has an effect in another subunit at a site distant from
the initial binding site. Hemoglobin also exhibits both "homotropic" and
"heterotropic" allostery: heterotropic in that binding of oxygen promotes
binding of the same molecule at another site; and homotropic as binding
2,3-bisphosphoglyceric acid allosterically decreases oxygen affinity at other
subunits [6]. The effect of pH on oxygen affinity to hemoglobin is also an al-
losteric effect, as protonation facilitates salt bridge formation that stabilises
the low oxygen affinity state. So the importance of allostery on important
biological mechanisms has been known for some time, and so utilising this
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for drug design is of considerable therapeutic interest.
Most early models also consider allostery to be a property of multimeric
systems. But allostery is ubiquitous throughout the proteome; and in fact
it has been suggested that all proteins could be allosteric [7]. This seems
quite possible, since a vast array of processes utilise allostery for regula-
tion and control of biological mechanisms, and is crucial for both long and
short range signalling pathways [8]. The importance of correct cell sig-
nalling cannot be over-emphasised: cells must be able to respond to very
subtle changes in environment, or face problems with cell development,
cell growth, and cell survival. Ultimately all of these responses to envi-
ronment are a result of allosteric effects. The definition of allostery also
encompasses various forms of allosteric "trigger" as was discussed with
hemoglobin: this could be homotropic or heterotropic allostery by binding
of a small molecule; binding of an ion; binding of another protein; a muta-
tion; or in response to light [9] or pH changes. Allosteric mechanisms are
responsible for many regulatory processes and information transfer, over a
wide range of important biological processes, yet a detailed description of
the mechanism involved has proven difficult. On binding of a ligand in a
region which is distinct from the active site, termed the allosteric site, some
conformational or dynamic change then ensues, which affects the binding
of another molecule at the active, or orthosteric site.
How this signal is transmitted from one site to another has been the topic
of much research [10, 11], and yet sufficient information is not yet available
to be able to design drugs to routinely target these sites. While some sys-
tems have fairly well understood structural changes [12], there has been no
overall description [13], which can applied over a range of allosteric pro-
teins and be used to predict the effects of ligand binding.
1.2 Structure based drug design
In the 1950s and 60s the first crystal structures of proteins were obtained by
Max Perutz and John Kendrew, who developed the method of protein crys-
tallography and solved the structure of myoglobin [14], and then hemoglobin
4 Chapter 1. Introduction
shortly after. Around a decade later, they deposited the first PDB file in the
protein data bank, structure 1MBN. The insights they gained from analysis
of these structures helped to develop understanding of sickle cell anaemia,
and won them a Nobel prize in 1962. Since then, the availability of 3D struc-
tures of proteins has expanded massively, with now over 150k structures
available in the protein data bank. This has been instrumental to the de-
velopment of our understanding of protein function, and ability to design
drugs. Understanding of structure and function of proteins is extremely im-
portant, however the crucial aspect for drug design is that crystal structures
also give information about the location and environment of ligand binding
sites, and this is the basis of structure based drug design (SBDD).
Computer aided drug design facilitates the ability to rationally design
drugs, and has now become a routinely used method in drug discovery.
Initial methods relied on use of static structures, for example docking [15],
or using scoring functions [16]. Molecular simulation allows for the study of
dynamics of proteins at atomistic level. Accuracy and speed of simulations
of protein dynamics has seen rapid advances in the last decade, and it is
now possible to simulate large systems to reasonably long timescales (µs to
ms) [17].
1.3 Drug design and allostery
In the last century, the vast amount of efforts in drug design have been
aimed at small molecules which bind at the active site of proteins. This
could be to inhibit enzyme function, to alter the behaviour of receptors, or
membrane channels [18, 19]. However often problems of selectivity are an
issue, and some particular drug targets were deemed "undruggable" due to
lack of suitable selective inhibitors.
Allostery presents an untapped resource of potential drug targets. Bind-
ing a drug at a site which is distant to the active site has numerous ad-
vantages in both selectivity and efficacy. It is often the case that the active
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site across families of proteins are similar: a result of evolutionary pres-
sure. Conservation of residues at the active site makes a lot of sense; en-
zymes carry out a very specific function, and are often highly specific in
the substrates they bind. Any mutations or variation of the residues di-
rectly involved in catalysis or substrate binding would likely have a nega-
tive outcome on functionality, and are therefore not tolerated. This makes
selective drugs extremely difficult to develop. Binding sites distant to the
catalytic centre are far more likely to tolerate mutations without affecting
overall function, so allosteric sites have far more potential to be selective.
In addition, that the ability to tune inhibition, or even activate function of
enzymes, will give allosteric drugs the edge over traditional active site com-
pounds. Furthermore, this process can be either reversible or irreversible:
since allosteric compounds can partially inhibit or activate function, it is
even possible to include covalent drugs, which would bind irreversibly to
their targets. Yet holding back development of these drugs is the limitations
of our understanding of allosteric mechanisms, and progress will need to
be made before routine, rational design, will be possible. Predictive tools
which can guide compound design are essential.
Allostery has historically been understood as a structural phenomenon,
in that binding induces some conformational change. But conformational
selection is far more in line with our current understanding of protein be-
haviour. This is where the MWC model was in part correct, although de-
scribing only a two state system, the idea of conformational selection was
apparent. The result of binding is a shift in equilibrium, rather than a struc-
tural change induced by binding.
This seems much more reasonable an explanation for allostery. As it is
well understood that protein behaviour is statistical in nature, where many
conformations of the protein are accessible, and the distribution of confor-
mational states define a conformational ensemble around the native state
[20]. Allostery is a result of shifting of states: where binding of a ligand
at a site distant to the active site favours a particular conformational state,
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and results in shifting of the population of these states by pushing the equi-
librium in that direction. Allostery can be seen without significant confor-
mational change, and many studies, even as early as the 1980’s [21] have
shown dynamical changes only as a method of allosteric regulation. If an
allosteric modulator selects a particular conformation for binding, how can
these subtle changes relate to changes in activity, and how can we under-
stand this process well enough to exploit it for drug design? It is also very
possible that allostery is a combination of both conformational selection and
induced fit [22], where a particular conformation selected for binding is then
stabilised, and allows for smaller adjustments to reach the catalytically ac-
tive state after binding [23–25].
Molecular dynamics (MD) simulations are routinely used to investigate
protein behaviour in atomistic detail. Understanding protein dynamics from
vast quantities of simulation data is already extremely difficult: add then
the complexity and diversity of allosteric mechanisms, and the challenge
becomes even harder. For a MD simulation of a protein, motions of hun-
dreds of residues (thousands of atoms), are computed. How can we dis-
tinguish relevant motions or functionally useful interactions relevant to al-
lostery, from stochastic, non-functional thermal fluctuations? Development
of tools which can extract useful information are important, as is the ability
to relate these dominant motions and important structural features to actual
differences in activity. To understand allostery, difficulty also lies in relating
how particular local, and often subtle structural change, results in global
functional changes, and how the specific structure of a ligand can facilitate
this. It is not always clear what structural differences can be observed be-
tween the inactive and active conformations of a protein, and can be even
more difficult when considering varying degrees of activity (i.e. strong acti-
vators vs. weak activators), so methods to highlight subtle differences must
be available. Considering allostery under the framework of conformational
selection; we must also understand how a particular conformation is best
suited for allosteric drug binding.
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Yet allosteric sites present an opportunity for selective drugs, in par-
ticular for highly sought after targets such as kinases, GPCRs (G protein-
coupled receptors) or extremely challenging or otherwise "undruggable"
targets such PTPs (Protein Tyrosine Phosphatases); therefore development
of methods to improve rational design are crucial. Allostery also offers
"tunable" modulators. While active site inhibitors can only inhibit, and
can only completely switch off the function of the protein, allosteric mod-
ulators can activate (to varying degrees), inhibit, or even partially inhibit.
The main issues with development of allosteric drugs is due to an incom-
plete mechanistic understanding of allostery, and how particular molecules
achieve varying degrees of allosteric activation or inhibition. Furthermore,
allosteric sites are often far more shallow than active sites, as many are usu-
ally protein-protein interfaces (PPIs) and therefore do not have the same
potential to bind a small molecule with high affinity than the active site.
Therefore it is extremely important to have methods which can not only
identify effective allosteric sites on proteins, but also gain some mechanis-
tic understanding to allow rational design of compounds that bind to these
sites and have the desired effect on activity.
Many approaches have been developed to tackle these challenges; and
is is likely the case that we require many different parallel approaches in or-
der to fully understand allostery. In the last 15 or so years, there has been a
surge in the interest in allosteric sites, which can be seen in figure 1.2, how-
ever the number is still small relative to the work done on active site com-
pounds. Many methods to attempt to define an underlying mechanism for
allostery, or to predict allosteric effects have been developed. Often, compu-
tational methods rely on analysis of MD trajectories, followed by some form
of dimensionality reduction, such as Principal Component Analysis (PCA)
[26–29]. PCA aims to explain the majority of variability in the data within in
a few collective modes, rather than the 3N dimensions for N atoms. Alter-
natives to MD include simplification of the conformational energy surface
using techniques such as Normal mode analysis (NMA) [30]. NMA relies
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FIGURE 1.2: Number of publications with
keyword "allostery".
Data obtained from: www.webofknowledge.com [33].
on using only one protein structure which represents the lowest energy con-
formation. Normal modes are then calculated as eigenvectors of the Hes-
sian matrix. Another increasingly popular methodology to study protein
allostery is Elastic Network Modelling (ENM) [31, 32]. This method simpli-
fies dynamics by representing the protein as an interconnected network of
springs. Different levels of detail are possible, with particles either repre-
senting atoms, or groups of atoms. A model is then constructed around the
most stable conformation and dynamics approximated as harmonic motion
around this structure. Each of these methods have advantages and draw-
backs, and combinations of techniques may be more appropriate, depend-
ing on the system under study.
These methods rely on allostery being explained by structural descrip-
tors. However it is important to realise that allosteric effects may arise from
very subtle changes in conformation or even dynamics that may be difficult
to observe structurally, however may be validated by considering changes
in energetics. Slight shifts in distributions of interaction energies or torsions
could be deciding factors on enzyme activation or inhibition, therefore sen-
sitive methods that also evaluate energetics are required to capture these
subtleties.
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1.4 Models to describe allostery
Initial descriptions of allostery were based on the haemoglobin oligomer, as
structural details were available for this system, and described allostery in
terms of cooperativity between adjacent chains. At this point, two mecha-
nisms were predominant in explaining protein allostery which were briefly
discussed in section 1.1, and while both are now known to be inadequate
descriptions, they provided initial key insights into a complicated process,
and could describe some of what was seen experimentally. Both were pro-
posed in the mid-1960s; over a decade before molecular dynamics had been
used to simulate proteins [34, 35], and so were at a point where atomistic
descriptions of the dynamics of biomolecules were not possible. Nonethe-
less, they allowed significant insights into this complex process, and current
models are expansions of these ideas. The Monod-Wyman-Changeux [2]
(MWC) model describes allostery as a concerted process (figure 1.1), where
the protein is either one of two states, an inactive and active form (termed
tensed T, and relaxed R). Inter-conversion between the two occurs without
the need for ligand binding and the population of each state is dependent
on a thermal equilibrium. Binding of a ligand to either state then shifts this
equilibrium in one direction or another, depending on whether the ligand is
an activator or inhibitor. The result is that the allosteric effect is dependent
not only on the concentration of bound ligand, but also on the equilibrium
between the two states. Around the same time, Koshland, Némethy and
Filmer [4] proposed another model (KNF model, which proposes that the
active form, exists only in presence of the ligand via an "induced fit" mecha-
nism. Activation of one subunit or binding site would then affect the bind-
ing of other subunits/binding sites, either by increasing or decreasing the
affinity of the others. This explained something that the MWC model could
not; negative cooperativity. Between the two models there is both agree-
ment and conflict. Both models suggest that the protein can exist in two
particular states, however one implies that these two states already exist
in equilibrium, while the other suggests that the activated state only exists
after ligand binding. Both models imply that allosteric proteins consist of
more than one protein chain, although it is now known that even single
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FIGURE 1.3: Conformational selection model for allostery.
Many states exist, and binding of allosteric inhibitor stabilises
inactive conformation.
monomeric proteins can undergo allosteric modulation.
The development of new experimental techniques [36] and molecular
dynamics simulations [34, 35] changed the understanding of many aspects
of protein dynamics and allosteric regulation. A recent description of al-
lostery is based on conformational ensemble theory [37]. According to this
model, proteins exist in a huge range of conformational states around their
native state [38, 39], and the distribution of these states defines the con-
formational ensemble. Allosteric effects are a result of shifting of the dis-
tribution of these states, which occurs due to changes in the stability of a
particular state caused by binding of an allosteric ligand (Figure 1.3). It is
possible to stabilise different states, for example inhibitors will stabilise the
inactive conformation, and activators the active conformation.
It is important to highlight that no new states are created according to
this theory, but only a shift in the distribution of already existing states [40].
For example, binding of an activating ligand would stabilise a particular
conformation of the protein which leads to products, and so move the equi-
librium in this direction. Whereas, binding of an inhibitor would stabilise
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the inactive conformer, and so reduce activity. Conversely, a structural view
of allostery suggests that some conformational change occurs on binding of
a ligand. This results in some form of correlated motions, which transmit
a "signal" from the allosteric site to the orthosteric site, leading to changes
in reactivity. In this model, it is not simply stabilisation of an existing con-
former, but instead is more in line with the "induced fit" explanation of en-
zyme activity. To understand the conformational changes associated with
an allosteric effect, the overall dynamic changes in conformation must be
considered, as static images of either end state of the protein do not help in
any understanding of how this change propagates from one site to another
in order to affect this equilibrium. Two models of signal propagation have
been suggested [41]. The first involves a series of successive motions from
one site to the other via one pathway, which has been termed the "domino"
model. The other model (the "violin" model) describes the signal via many
smaller pathways, with changes in vibrational patters being responsible for
the allosteric response (figure 1.4).
Although it is often the case, allosteric events do not necessarily im-
ply vast conformational changes. In fact, correlated changes of a few tor-
sional angles can result in very similar conformations, but direct certain
key groups in slightly different ways which promote catalysis. Similar to
the suggestion of the "violin" model, others had noted that conformational
change is not even required [42], and that allosteric responses may “travel
across the structure as an ‘energy signal’", in some cases more related to changes
in dynamics than conformational changes [21, 43] . This theory was devel-
oped in the mid-80s, and describes allosteric effects as a result of changes in
thermal fluctuations. Although this theory was presented some time ago, it
was only relatively recently [44] confirmed experimentally, in the case of the
protein calmodulin. While the two models of conformational ensembles, or
structural changes seem independent from one another, some studies have
shown that they may both be simultaneously valid [40]. It is also possible
that not all allosteric proteins will fall under the same sort of mechanism. In
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FIGURE 1.4: Figure taken from reference [41]. The
"domino" model describes the allosteric effect as conforma-
tional changes which occur sequentially from one site to an-
other. The "violin" model suggests that binding an allosteric
ligand affects many regions of the protein, and is not a direct
pathway. This could be structural or dynamic changes and af-
fect multiple regions of the protein, which include the active
site.
some cases, clear conformational changes occur, while in others allosteric ef-
fects can be seen with no significant conformational change. Therefore tech-
niques that capture both the obvious and the subtle changes are required in





In order to describe the dynamic properties of a system using MD simu-
lations, there are several concepts from statistical mechanics which should
first be defined.
In principle, to determine the macroscopic properties of a system, the
solution of Newton’s equations of motion over infinite time would give this
result, if the system is ergodic. However, this is only useful for very small
systems with only a few interacting particles, and is completely impossible
for systems such as proteins with thousands of atoms. Therefore, we rely
on computing distributions of configurations of the system using statistical
mechanics, and using some assumptions, allow us to replicate the macro-
scopic properties of a large system of interacting molecules.
2.1.1 Ensembles
In statistical mechanics, an ensemble is a collection of different microscopic
states of a system, whose average properties correspond to those observed
for the system at the macroscopic level. Depending on the system under
study, different ensembles may be of interest when running simulations
(such as molecular dynamics). For example the canonical ensemble (NVT:
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constant number of atoms, volume and temperature) or microcanonical en-
semble (NVE: constant number of atoms, volume and energy). The isother-
mal–isobaric ensemble (NPT: constant number of atoms, pressure and tem-
perature) is often used as it replicates the conditions under which chemical
reactions are generally carried out experimentally.
2.1.2 Ensemble averages
Ensemble averages, as the name suggests, allow calculation of mean val-
ues of the observables of the system as a function of individual microstates;
so while each microstate may have a different value for a particular prop-
erty, the mean value will remain constant. The ensemble has a well defined
property value that is postulated to correspond to the observable value in
the limit of a large number of particles in the ensemble. In molecular dy-
namics, the assumption is that each one of these microstates will be visited
proportionally to their Boltzmann probability over the length of the simu-
lation. Therefore averaging over time should result in the same value as
averaging over the large number of systems. This assumption, for a par-
ticular observable A, is that averages over time are equivalent to averages

















time, we must make several assump-
tions. First, it is important to note that individual microstates are not equally
likely. Different microstates will contribute to a macrostate with varying
weights, which depend on the energy of a particular microstate. Every in-
stantaneous configuration (or snapshot of a MD simulation) of all molecules
in the system represents a particular microstate. This configuration changes
over time as populations of molecules in each configuration will change.
The configuration of molecules in a particular microstate depends on the
weight of that configuration, which is dependent on the energy of the state
according to the Boltzmann distribution:







where N is the total number of molecules, Ni is the number of molecules
in state i, which have energy εi. The term β is a parameter which defines the
temperature (T) for which we want to calculate the most likely population





The distribution of states therefore only depends on the energy of each
state, and the ratio between any two given states (or the relative probability






where pi is the probability of state i, ε is the energy of a state, k is the
Boltzmann constant, and T is the temperature of the system.
2.2 Simulation methods
2.2.1 Force fields
For systems such as proteins, which contain many atoms, it is not possi-
ble to use quantum mechanics to describe the energy of a microstate as the
computation required would take too much time. Therefore methods which
describe atoms in terms of nuclear motions rather than electronic motions
must be employed, as this makes it possible to run calculations on very large
systems with many atoms within a reasonable time frame.
The energy of the system is described in terms of a potential energy func-
tion and a kinetic energy function, along with a set of parameters which are
obtained from experimental data or quantum mechanical calculations. The
combination of the potential energy function and parameter set is called
a force field, and many different force fields exist. The choice of force field
used will depend on the type of system being studied, as parameters will be
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optimised for particular cases, such as for proteins or for organic molecules.
The function which is used, includes terms to describe intramolecular mo-
tions (with terms for bond lengths, angles and torsions), and intermolecular
forces (with terms for van der Waals and electrostatic interactions). For ex-




































The first summation is associated with stretching of covalent bonds, and
is approximated by a simple harmonic equation, where k is the force con-
stant, li is the bond length at a given time, and li,0 is the equilibrium bond
length.
The second summation takes into account deviations from equilibrium
bond angles, where again ki is the force constant associated with this mo-
tion, θi is the angle and θi,0 is the angle at equilibrium. The third summation
is a function which describes energies involved in rotation about bonds. Vi
is associated with relative barrier energies, with higher values for types of
bond rotation which require more energy. The term n is the multiplicity [46],
which describes how many minima in energy will be involved to complete
a full rotation. γ describes where these minima are, and ω is the torsional
angle. The last double summation in this function describes all pairwise
non-bonded interactions, which defines van der Waals interactions using a
Lennard-Jones potential and electrostatics with a Coulomb potential. In the
Lennard-Jones equation, rij is the distance between two atoms i and j, ε de-
scribes the well depth and σ is the distance for rij which has energy equal to
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zero. These are illustrated in figure 2.1. In the Coulomb potential, qi and qj
are partial charges on atoms i and j, ε0 is the vacuum permitivitty, and rij is
the distance between two atoms i and j.
2.2.2 Long range interactions
In practice, it is too computationally expensive to calculate long range non-
bonded interactions for every pair of atoms in the system. Usually, for the
Lennard-Jones potential this is handled by truncation of the function at a
certain cutoff distance, as shown in figure 2.1.
FIGURE 2.1: Lennard-Jones potential describing the non-
bonding component of the potential energy arising from van
der Waals interactions. A cutoff is applied at a distance rcuto f f ,
above which interactions do not contribute to the potential en-
ergy.
In order to avoid a discontinuous function, a switching function (S(r))
is often added to reduce the value of the function gradually to zero as it
reaches the cutoff distance (rcuto f f ), as detailed in equation 2.6.
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ELJ =

ELJ(r) when r ≤ rs,
ELJ(r)S(r) when rs ≤ r ≤ rcuto f f ,
0 when r > rcuto f f
(2.6)
However treatment of the Coulombic term at long distances is less straight-
forward, as electrostatic interactions can occur at longer distances than those
from dispersion. Different methods can be applied such as PME (particle
mesh Ewald), or the Reaction Field method.
Using the PME method [47], electrostatics are treated differently depend-
ing on either they occur at longer or shorter distances. An Ewald summa-
tion involves the treatment of longer range distances to be calculated using
a summation in Fourier space which is possible due to periodicity, and the
short range interactions are calculated with direct summation in real space.
PME is a method which allows the approximation of this Ewald sum to be
done numerically [48].
EElec(Ewald)(r) = Eshort(r) + Elong(r) (2.7)
Where Eshort are the short distance interactions, and Elong are the long
distance interactions, at a distance r. These can be defined as:
Eshort(r) = ∑
i,j





where Ũ is the Fourier transform of the potential, and p(k) is the Fourier
transform of the charge density.
In the reaction field method [49, 50], a cutoff (rcuto f f ) is applied to each
atom in the system, which allows for all interactions within the cutoff to be
treated explicitly, and outwith the cutoff there is a medium with uniform di-
electric constant (εRF), which can be polarised by interaction with molecules
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where ∑b µb is the summation of dipole moments for molecules within
the cavity. The potential then becomes:
EElec(RF) = ECoulomb + ERF (2.11)
Where ECoulomb is the term shown for the Coulomb potential in equation



















The computational method of molecular dynamics [35] is based on a numer-
ical and sequential solution to the classical equations of motion (equation
2.13) in order to obtain information on the macroscopic properties of the
system. Starting with an initial arrangement of atoms, and by randomly as-
signing velocities based on the Maxwell-Boltzmann distribution, forces can
be calculated by differentiating the energy function which describes inter-
actions with neighbouring atoms. The acceleration is then computed from
Newton’s second law, and the particle is then moved to a new position. This
is then repeated for a series of timesteps, and during each step the force re-
mains constant. Hence the calculation must be broken down into a series of
many, very short, timesteps.







In equation 2.13, ~F is the force of a particle, m and ~a are mass and ac-
celeration respectively,~r is the position vector, and U(r) is potential energy
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function, described by a force field. Integration of each position and ve-
locity at each time step defines a trajectory, from which a wide range of
structural and dynamical information can be obtained, as well as thermo-
dynamic properties.
2.2.3.1 Integration methods
In order to propagate the dynamics of the system, numerical methods to
solve the equations of motions are required. Common integration algo-
rithms are variations of Verlet integration. An initial configuration of the
system (usually obtained from a X-ray crystallographic structure), defines
positions for each particle at t = 0. The algorithm then considers that the
positions of the particles in the system can be approximated by a Taylor
series:
r(t + δt) = r(t) + ν(t)δt +
1
2
a(t)δt2 + ... (2.14)
where r is the position of the particle, ν is the velocity, a is the accelera-
tion, t is the time, and δt is the timestep. Positions for time t− δt can then
be defined as:
r(t + δt) = r(t)− ν(t)δt + 1
2
a(t)δt2 (2.15)
Therefore to define the new position at time t + δt, the summation of
equations 2.14 and 2.15 can be combined, to give:
r(t + δt) + r(t− δt) = 2r(t)− r(t− δt) + a(t)δt2 (2.16)
The Velocity Verlet algorithm [51] is an extension of the above, which
in addition to position also calculates velocity at each δt. The Leap-frog
algorithm is similar to the Velocity Verlet, however instead of calculating
both directly at time (t + δt), velocities are calculated first at time (t + 12 δt,
followed by calculation of positions at time (t+ δt). This results in velocities
being calculated at different time to the positions, which can be corrected
using the following equation:













The timestep δt is selected such that sufficient conformational space can
be sampled, but also provide numerical stability. If δt is longer than the
timescale of the fastest motion, the energy of the system will not be con-
served.
2.2.3.2 Periodic boundary conditions
FIGURE 2.2: Periodic boundary conditions.
There is a limit to the number of particles which it is possible to simulate
using molecular dynamics at a reasonable computational cost. Boundaries
must be carefully considered, otherwise the ratio of surface molecules to
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bulk will be too high, and surface effects become an issue. Periodic bound-
ary conditions allow the particles which are near the edges of the box to be
treated as if they were in the bulk. As a particle moves out of a particular
box, it is replaced by an identical particle that appears from the opposite
side of the box. Therefore the number of particles within each box remains
constant (Figure 2.2).
2.2.3.3 Thermostats and barostats
Depending on which thermodynamic ensemble molecular dynamics is be-
ing run under, pressure and/or temperature may need to be fixed around
a certain value during the course of the simulation. Various methods exist
to achieve this, and ensure that average values of pressure or temperature
remain constant.
Thermostats
It is important to control the temperature of the system during an MD
simulation, which is calculated from the kinetic energy using the equiparti-
tion theorem. The instantaneous temperature of the system is likely to vary
from the temperature selected to run the simulation, however by averag-
ing over many instantaneous temperatures, the target temperature should
be achieved. Thermostats are required to ensure that these time averaged
values are constant, and ensure that the correct ensemble is sampled. Dif-
ferent algorithms have been designed in order to adjust the solution to the
equations of motion in order to maintain an average temperature required
for the system under study.
The Berendsen thermostat [52] is a weak coupling algorithm, which us-
ing a scaling factor to alter the momenta of molecules to that of the tem-
perature set for the simulation. This ensures that the kinetic energy of the
system is that of the required temperature. However there are some issues
which can result from use of this thermostat, which leads to an uneven dis-
tribution of energy between the different degrees of freedom, and therefore
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does not maintain the equipartition theorem that energy is divided equally
by all degrees of freedom.
The Andersen thermostat [53] adjusts temperature by selecting a par-
ticular molecule and adjusting the temperature of that particle by altering
the velocity from the Maxwell-Boltzmann distribution for the temperature
defined for the simulation. This can cause artefacts in the dynamics, as it re-
lies on sudden changes in velocity. Other thermostats such as Nosé-Hoover
[54, 55], or the Langevin thermostat may improve on some of these issues,
however each have individual benefits and drawbacks.
Within this work, the Andersen thermostat was used, as it is the only
thermostat implemented in the software used to run the majority of MD
simulations, SOMD (Sire/OpenMM) [56]. However, care was taken to check
for issues that can occur with use of this thermostat, by monitoring back-
bone RMSD.
Barostats
In order to replicate experimental conditions, it is often desirable to sim-
ulate the system under the NPT (or isothermal-isobaric) ensemble. In order
to maintain a constant average pressure, a barostat algorithm is used. The
Berendsen barostat [52] works in a similar way to the Berendsen thermostat,
in that the volume is altered by some scaling factor by addition of terms
to the equations of motion, to allow fluctuations in the pressure to remain
around the target pressure. The Monte-Carlo barostat adjusts the pressure
by assessing both the positions and the volume of the system at alternating
timestep. The movement of a particle is either accepted or rejected based on
the Metropolis criterion. To alter the volume of the system, a random expan-
sion or compression is applied, and either accepted or rejected depending
on the ratio of energies before and after the adjustment. Other barostats
such as Andersen [53], Nosé-Hoover [55], and Parrinello-Rahman [57] are
commonly used.
In all simulations run with the software SOMD (Sire/Open MM) [56],
the Monte-Carlo barostat was used.
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2.3 Information theory
2.3.1 Kullback-Leibler divergence
Often, methods to analyse molecular dynamics trajectories involve analysis
of probability distributions of some parameter obtained from the the MD
simulation. There are many statistical methods to determine differences be-
tween these distributions of data to gain useful information. F-divergences
are functions which provide information on the distance between two prob-
ability distributions. One such function is the Kullback-Leibler [58] diver-
gence (KL). Starting from a reference distribution (e.g. obtained from a
molecular dynamics simulation), the distance is measured to reach a tar-
get distribution (from another simulation, of the same or different system).
For example, by taking a reference distribution from a simulation contain-
ing a protein only and the target distribution from a simulation of a protein
and ligand complex, the divergence of the target from the reference distri-
bution can be obtained. This essentially gives information relating to the
extent of differences between probability distributions, otherwise known as
the relative entropy. Calculation of the KL divergence of a particular ob-
servable can allow quantitative comparisons of different systems. The KL
divergence is defined for a discrete distribution in equation 2.18, where P
and Q are the probability distributions from the target and reference en-
semble respectively, N is the number of bins, and P(i) or Q(i) are the counts
of the i-th bin in distribution P or Q.








This is taken to mean the distance of distribution Q from distribution P,
and is described as such due to the asymmetry of the relationship, in that
DKL(P||Q) 6= DKL(Q||P). The value of the distance between two distribu-
tions is always greater than, or equal to zero, with a value of zero only if the
two distributions are identical.
Even if considering two separate molecular dynamics simulations of the
same system, it is likely that the KL value will not be zero as some statistical
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variation is expected, due to finite sampling. If the term P(i)Q(i) in equation 2.18
is replaced only by P(i), then this equation is a measure of the entropy of a
distribution, however by taking this ratio, a difference between the two dis-
tributions is defined. In the case where distributions P and Q are completely
continuous, equation 2.18 gives a solution. An issue arises when comparing
probability distributions which are not continuous, as either P(i) or Q(i) is
equal to zero, leading to an undefined divergence. One approach to resolve
this issue is to add a prior count to all histogram bins. The simplest prior
adds a uniform amount to each bin as described in equation 2.19 to give a
new distribution P′.
P′(i) = P(i) + xP (2.19)
In this equation, P(i) represents bin number i from the original distribu-
tion, x represents a fraction which influences the size of the value added and
P represents the mean of the original distribution P. Therefore all bins con-
tain a non-zero value, and assuming this prior count is significantly smaller
than the probabilities obtained from the data, the KL value obtained should
still be representative of the distance between those two distributions. How-
ever, a problem arises using this method when the differences in overlap
vary considerably between systems. For those which have only a small re-
gion which is non-overlapping, the effect will be different to those with a
larger non-overlapping region. Therefore comparison of these two cases
would be difficult. To resolve this issue, a fixed value can be split over only
the bins which have a zero count, therefore adding differing values per bin
depending on the number of empty bins. This should allow weighting to
compensate for the differing number of empty bins. Methods to determine
how many bins (N) to use to plot a histogram vary considerably, and there is
no general rule which will suit all data. One commonly suggested method
is to use a number of bins equal to the square root of the number of data
points. This gives a good initial estimate for an appropriate number of bins,
however as no one method suits all data, a range of bin numbers must be
tried, in order to determine how this affects the resulting distribution. Test-
ing must be carried out to establish how the number of bins used affects the
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KL value obtained, and on the value used for x. An example of such tests
can be found in section 3.3.3.1.
2.3.2 Jensen-Shannon divergence
In some cases, it may be more useful to have divergence values which are
symmetric to both variables P and Q. While KL divergence is acceptable to
use when comparing all to the same reference (i.e. the inhibitor bound sim-
ulation is always Q (reference), while P is any activating ligand bound sim-
ulation), it is less useful if we want to compare many different compounds
to each other as we cannot always select the same reference. In this case, we
compute the Jensen-Shannon divergence which is symmetric.
JSD(P ‖ Q) = 1
2
D(P ‖ M) + 1
2
D(Q ‖ M) (2.20)
2.3.3 Mutual information
Various structural differences may be observed between different ligand
bound simulations, however determining which are responsible for differ-
ences in activity is challenging. In order to describe this, Mutual Informa-
tion (MI) can be used to show correlations between different variables. MI
is able to capture higher order correlations where small changes in one pa-
rameter cause larger changes in another. Taken from information theory, MI
describes the amount of information which one variable contains about an-
other variable. MI can take any value from 0 to +∞, however normalisation
is commonly done to yield values between 0 and 1 (where 1 is completely
correlated and 0 means completely uncorrelated).
To mathematically define MI, we should first introduce the concept of
information entropy. Analogous to the equation which describes entropy in





P(xi) logb P(xi) (2.21)
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This defines the entropy for a variable X, which can have values belong-
ing to (X) = {x1, x2, x3, .., xn}. The units of entropy depend on the base on the
logarithm, where base 2 results in units of "bits", base e gives units of "nats",
and base 10 is units of "bans".
Information entropy defines how much information is contained in a set
of one variable. Mutual information then extends this, to define how much
information we can obtain from one variable, by observation of another dis-
tinct variable. Therefore we utilise this in molecular dynamics simulations,
in order to define how correlated two different variables are.
The MI of two discrete variables X and Y is defined as:










Where X and Y are two different variables, where variables X and Y can
have values {x1, x2, x3, .., xn} and {y1, y2, y3, .., yn} respectively, and probabil-
ity distributions of P(X) and P(X).
The relationship of MI to information entropy can be expanded by con-



















From here we can define MI as:
I(X; Y) = H(X)− H(X|Y) (2.25)
Or as:
I(X; Y) = H(X) + H(Y)− H(X, Y) (2.26)
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In practice, because distributions are obtained from finite samples, it is
possible to observe artefactual correlations between independent variables
using MI. To account for this, a correction was made to subtract a value
associated with noise. This was achieved by computing MI with one of the
two variables randomised in time (Xrand). Therefore, MI reported in the
results is as follows:
Icorr(X; Y) = I(X; Y)− I(Xrand : Y) (2.27)
2.3.4 Principal component analysis (PCA)
In order to extract information from MD trajectory, motions which are im-
portant for biological function must be identified. Considering only Cα
atoms, a protein simulation with 286 residues (as for PDK1) would have 858
dimensions. Finding which motions are functionally important in this high
dimensionality space is not trivial. Methods which highlight major collec-
tive motions are needed, to reduce the dimensionality into a few important
modes (principal components). In most PCA studies of protein dynamics,
the implicit assumption is that the dominant collective modes found by this
technique are the main functional modes, i.e. larger variance components
are dynamically interesting, while others are ‘thermal noise’. This is because
it is often the case that the functionally relevant motions of a protein involve
displacement of many atoms at the same time, and so Cartesian coordinate
PCA can be used to highlight these functionally important modes. To use
PCA to study smaller, yet functionally relevant local motions, it is possi-
ble to select a subset of atoms/residues and perform PCA over this subset
of atoms, thus highlighting smaller amplitude motions which could be im-
portant. This approach could be useful for applying PCA to understanding
allostery, as functionally relevant differences in structures are likely to be
located between active and allosteric sites, and do not always involve large
differences in overall structure.
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PCA is a multivariate statistical method which allows reduction of the di-
mensionality of a molecular dynamics trajectory by projecting a set of N-
dimensional data onto a new coordinate space, where the first few new di-
mensions explain the largest variance in the dataset. This makes it possible
to describe a large percentage of the overall variance in the data using only
a few principal components (dimensions) rather than the original N dimen-
sions of the original dataset.
For a set of data X, PCA aims to construct a new set of variables Y, such
that:
Y = W ′X (2.28)
Where W ′ is a term obtained from the PCA, which results in the variables
of Y being a weighted average of the original set of variables. W is obtained
from the covariance matrix, as described below. Covariance is defined as:
Cov(A, B) = ∑
n
i=1(Ai − A)(Bi − B)
n
(2.29)
where n is the number of degrees of freedom, Ai and Bi are values for
two different degrees of freedom, and A and B are their mean values. Pos-
itive covariance means that both Ai and Bi are correlated, while a negative
covariance means Ai and Bi are anti-correlated. A value of zero covariance
means that Ai and Bi are completely uncorrelated.
A covariance matrix is then constructed with the format:
∣∣∣∣∣∣∣∣∣∣
Variance(x1) Covariance(x1, x2) ... Covariance(x1, xn)
Covariance(x2, x1) Variance(x2) ... Covariance(x2, xn)
... ... ... ...
Covariance(xn, x1) Covariance(xn, x2) ... Variance(xn)
∣∣∣∣∣∣∣∣∣∣
Diagonalisation of the covariance matrix yields a set of eigenvectors (prin-
cipal components), each with an associated eigenvalue. The eigenvectors
are ranked by eigenvalue, and those with the highest eigenvalues are the
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principal components. A set of eigenvectors which have the largest eigen-
values are selected, and form a mxn dimensional matrix W. W ′ which is
shown in equation 2.28 is then the transpose of W.
From a MD trajectory, a covariance matrix is constructed for a particular
descriptor of interest. In this work, Cα coordinates have been used (264 Cα
for the PDK1 system), and so the covariance matrix will be 792 by 792 (as
x, y, z for each Cα) however other metrics such as torsional angles could be
used [59].
2.4 Energy decomposition
As was mentioned earlier, the functional form of the potential energy sur-
face is defined in equation 2.5. This is pairwise additive over all atom pairs
i,j, and so can be decomposed for every residue pair (I,J), by summing every
i,j atom pair interaction for atoms belonging to each residue.
From this, we can therefore obtain the contribution to U(r) which relates
directly to the non-bonding interactions by considering the terms within
the last double summation, which relate to the van der Waals interactions,
and electrostatic interactions. We can then decompose this potential energy
component into a pairwise value, which relates specifically to the interac-
tion of one residue in the system (a ligand, molecule, or protein amino acid)
to any other residue in the system.
2.5 Markov state models
A Markovian process defines a stochastic series of events, where probabil-
ities of future events are determined only by the current state, and not by
any preceding events. A Markov model is constructed of a set of discrete
states, which are connected by the probabilities from moving from one state
to another, referred to as transition probabilities.
The goal of building a Markov model from MD simulation data is to
transform the time series data obtained from MD trajectories into a series
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of discrete states, and then determining the transition probabilities between
each state in order to gain mechanistic insight.
To build a Markov mode, the following process is followed:
• Reduce dimensionality.
• Cluster to obtain microstates and assign structures to each microstate.
• Assign microstates to slowly converting macrostates.
• Estimate populations of each macrostate and transition probabilities
between each macrostate.
Clustering of the initial simulation data is used to construct a series of
microstates. The trajectories are then converted from a series of coordinates
over time, to a series of states over time. A lag time (τ) is defined as the
timestep for each transition from state i to state j. For a given lag time τ, a
transition matrix P(τ) is then constructed, such that:
P(τ) = [pij(τ)] (2.30)
In this equation, pij is the conditional probability of the transition from
state i to state j at a given lag time τ. The value for τ is selected such that
the processes of interest are well resolved, but also allows the model to obey
Markovianity. The implied timescales (ITS) for each process are determined





A timescale is selected which allows for the smallest value of τ for which
the ITS converge to a constant value, which is no longer dependent on the
value of τ. In equation 2.31, ti is the ITS of the ith process, λi are the eigenval-
ues of P(τ), and τ is the lag time. To confirm that the processes described by
P(τ) are Markovian, the Chapman Kolmogorov (CK) test [60] can be carried
out, which determines whether P(τ) obeys the CK property:
P(kτ) = Pk(τ) (2.32)
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P(kτ) is a MSM constructed by multiplying the lag time τ by a factor k,
and Pk(τ) is the MSM built at lag time τ to the power of k. The eigenvalues
and eigenvectors of the transition matrix P(τ) are then calculated. The sta-
tionary distribution (π) is given by the left eigenvector associated with the
highest eigenvalue (which is equal to 1) λ1(τ):
π>P(τ) = π> (2.33)
Further eigenvectors provide information on the dynamics, and coeffi-
cients of each eigenvector (λ2,....,λi) describe transitions into and out of each
state.
As the MSM is constructed using conditional probabilities between dif-
ferent states, it is not not required to comprehensively sample the process
of interest. This allows for a series of parallel MD simulations to be run in a
much shorter time [61] than if the same processes were sampled using long
equilibrium MD simulations.
2.6 Enhanced sampling methods
It is often the case that the particular motion of interest in a protein is not
sampled within the normal equilibrium MD timescales (in the order of µs)
and as it is not required to sample the full equilibrium distribution in order
to construct an MSM, shorter simulations started from a range of different
starting points can be used. In order to generate starting points for interme-
diate structures, different enhanced sampling methods can be used. In this
work, steered MD (sMD) [62] has been used.
It is possible to modify the Hamiltonian of the system in order to bias
the motion of a particular set of atoms or residues, to pull one region of the
protein along a particular collective variable, S.
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In equation 2.34, S0 and S are the initial and current values of the col-
lective variable, ν is the pulling speed and k is the force constant. Different
collective variables are possible, and combinations of different distances can







kinase-1 (PDK1) mediated by
covalently bound small molecules
3.1 Introduction
3.1.1 Protein kinases as a drug target
Protein kinases are a class of allosteric enzyme, which regulate activity of
their substrate proteins via phosphorylation [63]. The activity of the kinase
itself can be modulated allosterically, as they have binding sites which are
distant to the active site, which control the on/off switching of phosphory-
lation events. The functional effect of this phosphorylation on the substrate
protein is also often allosteric, in that phosphorylation of serine, threonine
or tyrosine at one site of an enzyme or receptor initiates a response at an-
other site of that substrate protein. Kinases have been extensively studied,
as they have been implicated in many different disease pathways, including
cancer, diabetes, and many others [64].
The catalytic domain of protein kinases comprises of an N and C ter-
minal lobe, with a binding site for ATP (the orthosteric, or active site) lo-
cated between the two lobes. Coordinated to ATP either one or two Mg2+
ions, depending on the particular kinase. The important structural features
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FIGURE 3.1: Common structural features of protein kinases,
illustrated using the structure of PDK1.
which can be found in all kinases are highlighted in figure 3.1, which is il-
lustrated using the protein kinase PDK1. In addition, most kinases have
a sequence which extends from the C-terminal lobe termed the hydropho-
bic motif (HM), which usually contains a phosphorylation site [65, 66]. The
structure of the HM is illustrated later in figure 3.7.
The human "kinome" (the set of all protein kinases which are encoded by
the human genome) comprises of at least 518 different protein kinases, mak-
ing them one of the largest families of enzymes and representing around
1.7% of human genes [67]. However this 1.7% can actually affect far more of
the proteome: up to 30% of all human proteins [68] are phosphorylated by
kinases. They are involved in the regulation of almost all important cell pro-
cesses, including protein synthesis, transcription, cell division and growth,
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and apoptosis. The 518 kinases are classified depending on which residues
they phosphorylate. Most of these are serine/threonine kinases (STKs), fol-
lowed by tyrosine kinases (TKs), and the remainder are capable of phospho-
rylating all of the above (DSKs - dual specificity kinases). The next classi-
fication is to split these into two groups: the majority (478), which have a
eukaryotic kinase domain (ePKs - eukaryotic protein kinases); and around
40 which do not (aPKs - atypical protein kinases) [67, 69]. Of the ePKs, there
are then 8 subfamilies, which are classified based on sequence similarity:
• CAMK (Ca2+ / calmodulin-dependent kinases)
• TKs (tyrosine kinases)
• TKLs (tyrosine kinase-like)
• CMGC (related to CDKs (cyclin-dependent kinases), MAP kinases (mitogen-
activated protein kinases), GSKs (glycogen synthase kinases) and CDK-
like kinases)
• STE kinases
• CK1 (casein kinase 1)
• AGC (related to protein kinase A, protein kinase G and protein kinase
C)
• RGC (receptor guanylyl cyclase)
Both phosphorylation and dephosphorylation are required to achieve
regulation. Phosphorylation of a protein or enzyme can affect the confor-
mation or dynamics, change the enzyme’s activity, or alter protein-protein
interactions. Often phosphorylation results in activation or inhibition of an
enzyme or receptor. This means that phosphorylation and dephosphoryla-
tion can act as a switch within complex signalling pathways, with protein
kinases carrying out the phosphorylation, and protein phosphatases the de-
phosphorylation. Signal transduction occurs by successive activation and
inhibition. Each of these steps must be tightly controlled, and dysregula-
tion at any one of these steps is often a contributing factor to many diseases.
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FIGURE 3.2: MEK1 kinase inhibitor E62 bound to the DFG-out
conformation from PDB ID 5HZE. The DFG-in conformation
of MEK1 is shown in grey (PDB ID 3W8Q).
Overexpression can lead to an over-abundance of a particular kinase, or mu-
tation can lead to a kinase which is incorrectly in a permanently active state,
leading to over-phosphorylation of its substrates. One broken link, and an
entire signalling pathway can be led astray, therefore the development of
approaches to selectively and accurately modulate activity are crucial.
As a result, kinases have been a focus for drug design for many years,
however the interest has historically been in active site compounds. De-
pending on the binding mode, there are two classifications of active site
compounds, type I or type II. The difference depends primarily on the con-
formation of the DFG motif, where type I binds the DFG-in, and type II the
DFG-out (Figure 3.2).
These are both ATP competitive, however type II inhibitors can occupy
3.1. Introduction 39
both the active site and an adjacent pocket. There are both type I and II
kinase inhibitors in use, however few are particularly selective. Type I in-
hibitors such as Gefitinib [70] or Bosutinib [71] bind directly at the ATP site,
and usually do so with some form of adenine analogue. Some include ex-
tensions which interact with other nearby sites, to attempt to promote se-
lectivity. However due to the high conservation of the ATP site, selectivity
is often poor and so other kinases are also inhibited, leading to adverse side
effects.
Type II inhibitors bind to the ATP site, however as they bind to the DFG-
out conformation, they have access to bind also to a pocket available only in
this conformation (figure 3.3). Some successes of selective active site com-
pounds have been for type II active site inhibitors for particular kinases,
such as Imatinib (otherwise known as Gleevec) [72]. Imatinib is an inhibitor
of several tyrosine kinases, and does so with reasonable specificity for Bcr-
Abl tyrosine kinases, which are expressed as constitutively active due to a
chromosome defect. Computational studies to determine the reasons be-
hind the specificity suggest that conformational selection plays a crucial
role. The findings suggest that Abl kinase has a preference for DFG-out
conformation even without ligand binding [73], which is the favoured con-
formation for binding of imatinib. However, in related kinases the DFG-in
conformation is preferred. While this has been an impressive development,
the mechanism of the selectivity was not discovered until much later, and
rational design of selective active site inhibitors is still extremely challeng-
ing. In addition, it may only be some specific kinases for which this is pos-
sible, as this conformational selectivity around the ATP site may only be
useful in select cases.
A further class of inhibitors of kinases are allosteric, or type III inhibitors.
This subset of molecules has been defined as those which bind directly next
to the ATP site, however do not compete with ATP binding (figure 3.4). The
first type III allosteric small molecule kinase inhibitor to be developed was
Trametinib, a MEK1/MEK2 inhibitor developed by GSK [74]. It is approved
only for treatment of adult patients with metastatic melanoma, with specific
mutations of the BRAF gene, which encodes a Ser/Thr kinase B-Raf.
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FIGURE 3.3: DDR1 kinase inhibitor imatinib binds at the ac-
tive site however extends into another pocket which is acces-
sible in the DFG-out conformation. Structure from PDB ID
4BKJ.
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FIGURE 3.4: MEK1 kinase inhibitor XL518 (PDB ID 4AN2)
bound at an allosteric site directly adjacent to the ATP bind-
ing site.
42
Chapter 3. Allosteric modulation of phosphoinositide-dependent
kinase-1 (PDK1) mediated by covalently bound small molecules
Further allosteric inhibitors are termed as class IV, which bind to a site
completely separated from the ATP site. Various sites have been discovered,
on both the N and C terminal lobes, depending on the kinase.
These distant allosteric sites are now known for many kinases, and both
small molecule and peptide inhibitors and activators have been discovered
[75]. Figure 3.5 highlights some of these known sites, overlaid on a struc-
ture of an AGC kinase, phosphoinositide-dependent kinase-1 (PDK1). The
allosteric site for PDK1 is shown later, in figure 3.11. In this figure, ATP is
bound to the active site in between the N and C terminal lobes, along with
two Mg2+ ions. In red, a peptide inhibitor for the epidermal growth factor
receptor (EGFR) kinase domain [76]. In green, compound 38 showed inhi-
bition of checkpoint kinase Chk1, and binds to a site located around 13 Å
from the active site, and with an IC50 of 1.3 µM [75]. A different allosteric
site has been discovered for Abl kinase, highlighted in purple, [77].
FIGURE 3.5: Structure of PDK1 with ATP and two Mg2+
bound at active site, and known allosteric sites for other ki-
nases overlaid. Red: PDB ID 4R3R. Green: PDB ID 3F9N. Pur-
ple: 3K5V. Teal: 3PXZ.
In teal in figure 3.5, an allosteric site in the N terminal lobe was discov-
ered for Cyclin-dependent kinase 2 (CDK2) [78], however in this case two
molecules bind to this region, and require a large shift in the position of the
α-helix C to accommodate one of them, as shown in figure 3.6. In this figure,
the teal coloured helix C represents the shifted helix, with two molecules of
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FIGURE 3.6: CDK2 allosteric site highlighting shift of helix C
(See Figure 3.1 for kinase structural features). Teal: crystal
structure PDB ID 3PXZ with two allosteric ligands. Purple:
CDK2 without allosteric ligand (PDB ID 3MY5). Orange: He-
lix C in PDK1. Grey: Both overlaid on structure of PDK1.
inhibitor bound. In orange, the α-helix C from PDK1 is shown, and in pur-
ple the helix position in another structure of CDK2 without allosteric ligand
(PDB ID 3MY5).
As of yet, there are no type IV kinase inhibitor on the market, however
they do offer a promising solution to the problems faced by the other three
classes of kinase inhibitor. As mentioned in section 1.3, evolution of en-
zymes relies on the conservation of the active site. Residues which are di-
rectly involved in the enzyme catalysed reaction are less likely to tolerate
mutations, so often the active site and surrounding region are highly con-
served. However if we target sites located away from this conserved re-
gion, it is potentially easier to find mutations which would allow selective
binding, as there is a higher chance that some residues vary between family
members. Also, as with type III inhibitors, there is the possibility to tune
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the inhibition. As these sites are non-competitive with ATP, it is possible to
achieve a range of inhibition depending on the conformation that the drug
can stabilise. It is even possible to increase the activity, as this can also result
in a desired therapeutic effect in some kinases [79]. In the case of active site
compounds for kinases or any other enzyme, direct activation is not possi-
ble, as the endogenous ligand binding is blocked.
Particularly an issue with kinase inhibition is that concentrations of ATP
in the cell are reasonably high (1 to 5 mM [80]). Therefore any active site
compound has to both succeed at competing with high ATP concentrations,
and do this selectively.
The IC50 of a drug is the concentration of drug required to obtain 50%
inhibition. However as active site kinase inhibitors are also competing with






Where Ki is the inhibition constant of the ligand, [ATP] is the concen-
tration of ATP, and KM,ATP is the Michaelis constant for ATP. For the high
cellular concentrations of ATP this then contributes to the difficulty of de-
veloping good active site inhibitors.
Since type IV allosteric sites do not compete with ATP, this is not an
issue. However a challenge with these type IV allosteric sites, is that as most
of these sites are effectively protein-protein interfaces (PPIs), they tend to be
far more shallow than the active site, leading to difficulties with potency due
to insufficient ligand affinity. An interesting approach to solve this solution
is the development of covalent allosteric drugs [81].
Covalent drugs are those which contain reactive groups which can bond
irreversibly with their target proteins. They have been in use for some time,
and in fact many were discovered even before their mode of action was
understood [82], however toxicity concerns have resulted in reduced inter-
est the development of new compounds [83]. With allosteric sites, toxicity
could be less of an issue, provided that off target covalent binding can be
avoided. This is easier with allosteric sites if non-conserved residues are the
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target of the covalent modification, as this then reduces the chances of bind-
ing to a related protein [81]. As drugs bind covalently, they do not require
the strong affinities of non-covalent drugs which rely only on non-bonded
interactions to maintain a stable drug-protein complex.
The selectivity improvement seen by targeting allosteric sites can also be
a source of a potential problem. As allosteric sites do not show the same
evolutionary pressure to remain conserved, they are more prone to tolerat-
ing mutations, and this is a benefit in terms of selectivity. However this also
could lead to subsequent issues with resistance, as if residues within the
allosteric site mutate, the drug may no longer be effective [84, 85]. Yet resis-
tance is also an issue for active site compounds, and so should not result in
reduced focus on targeting allosteric sites [86].
3.1.2 PDK1 3-phosphoinositide-dependent protein kinase-1
PDK1 (or PDPK1) is a master AGC kinase. "Master kinase" in that it phos-
phorylates other kinases (at serine or threonine residues), of which it is part
of the same family. In most kinases, a hydrophobic pocket exists within the
N-terminal lobe (highlighted in purple in Figure 3.7), and this can interact
with the hydrophobic motif (HM) which extends from the C-terminal lobe
of the same molecule. With PDK1, this hydrophobic motif is not present.
Instead, the hydrophobic pocket of PDK1 is involved when binding the
substrate protein, where the hydrophobic motif belonging to the substrate
can interact with the hydrophobic pocket of PDK1, and this instigates the
allosteric event, as shown in figure 3.7. The terminal region of the sub-
strate HM has been termed the "PIF" region, or "PDK1 Interacting Frag-
ment". Therefore the allosteric site which this binds to in PDK1 is named
the "PIF-binding pocket".
Substrate proteins must already be phosphorylated at their HM to in-
crease recruitment by PDK1 [65, 66]. This phosphate interacts with a pocket
directly adjacent to the PIF pocket [87], which facilitates the PIF binding to
PDK1. This binds to the catalytically active conformation of PDK1 and so al-
losterically activates PDK1, where the active site can then catalyse the trans-
fer of a phosphate to the substrate activation loop. Studies have also found
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FIGURE 3.7: PDK1 (green), highlighting the PIF-pocket (pur-
ple). ATP bound to active site, and P-Ser169 shown in sticks.
Substrate protein Akt in blue (PDB ID 1O6L altered to illus-
trate extended HM region). PDK1 interacting fragment (PIF)
of Akt higlighted in purple. Activation loop of Akt in cyan,
with P-Thr which is phosphorylated by PDK1 shown in sticks.
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the inverse allosteric effect can occur; in that binding of a small molecule
inhibitor at the active site can affect the binding a the PIF-peptide at the
allosteric site [88].
The structure of the PDK1 catalytic domain is illustrated in figure 3.1.
In addition to the catalytic domain, PDK1 possesses a pleckstrin homology
(PH) domain, which can recruit PDK1 to the membrane during specific sig-
nalling events [89]. PDK1 is inherently active, and [89] autophosphorylates
at Ser169.
Initial discoveries of allosteric modulators of PDK1 were peptides [90].
Inhibitors were only discovered as small molecules. This may be due to
the far more specific interactions of a small molecule, whereas the sum of
the activating and inhibiting interactions of the peptides do not result in
inhibition as suggested by Sadowsky et al [91], who stated that:
"It is possible that the activation of PDK1 observed by PIFtides repre-
sents the net sum of interactions between a number of subsites, some of
which can be activating and some inhibiting. Perhaps the small frag-
ments can occupy individual subsites and thereby generate more potent
activat- ing or inhibiting effects on PDK1."
The structures used as a basis for all simulations of PDK1 were devel-
oped by Sadowsky et al. [91], and include various covalently bound small
molecules (Figure 3.16) which are attached to the PIF pocket of PDK1. This
was achieved by an artificial modification of a residue within this pocket
to a cysteine, and a ligand could then be attached by a disulphide bond,
in a process known as "disulphide trapping". Various positions within the
PIF pocket were mutated, and one particular system was chosen for study
(T148C), as this was more selective in binding. To this cysteine residue,
several small molecules have been attached via a disulphide bond. Both
activator and inhibitor small molecules bound to PDK1 T148C were devel-
oped, and activity of the PDK1-disulphide complex was determined with a
kinase activity assay, using a substrate derived from the activation loop of a
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substrate protein, Akt. This substrate is likely to only bind at the active (or-
thosteric) site, as the sequence which was used in the assay (KTFAGTPEY-
LAPEVRR) would not be long enough to bind to both allosteric and orthos-
teric sites simultaneously. Phosphorylation occurs at the threonine residue
which is fairly central in this peptide chain, and this residue must be in close
proximity to ATP for phosphoryl transfer to occur. PDK1 binds ATP at the
orthosteric site, along with two Mg2+ ions which are crucial for catalysis.
In the crystal structures from Sadowsky et al., a non-reactive ATP compet-
itive ligand is present in the orthosteric site instead of ATP. Further crystal
structures were therefore considered in order to correctly place ATP and
magnesium ions within the binding site. In this, and many other kinases,
each magnesium ion tends to adopt octahedral coordination geometry [92–
94], with coordination to ATP, protein residues, and water molecules. The
residues which coordinate to magnesium vary between kinases, however




The first considerations when setting up this model involved the parameter-
isation of the ligand, as it was necessary to correctly describe a non-standard
disulphide bond, by which the ligands are attached to the PIF pocket. Pa-
rameters had to be set up for the ligand but include the correct description
of the ligand-cysteine bond, which is not a standard residue included in ei-
ther the GAFF [96] (General Amber force field; used for ligand) or Amber
[97] (used for protein) force fields. To generate a suitable set of parameters,
the X-ray crystallographic structures PDB IDs 3OTU (PDK1 with allosteric
activator JS30), 3ORZ (PDK1 with allosteric activator 2A2) and 3ORX (PDK1
with allosteric inhibitor 1F8) were used as a starting point, and in each case,
the coordinates of the allosteric ligand along with the Sγ and Cδ atoms from
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FIGURE 3.8: Ligand with atoms belonging to CYX residue,
with Cβ replaced by a hydrogen atom, used to generate ini-
tial partial charges using Antechamber. Atoms belonging to
CYX removed to balance charge to zero.
the Cys148 residue were retained, and Cβ was replaced with a hydrogen
atom (Figure 3.8).
For the resulting thio-ether, partial charges could then be derived using
the AM1-BCC methodology using Antechamber [98]. The partial charges
initially assigned were modified to replicate the bond of a bound cysteine
residue, as defined in the Amber force field. The atoms belonging to the
Cys residue were then removed as in figure 3.8, and overall charge on the
ligand was balanced (either to zero for uncharged, or +1 for protonated).
The coordinates of the ligand were aligned to the X-ray crystal structure of
the protein ligand complex using the software Pymol [99]. Three ligands
were initially developed in this way: two agonists (JS30 and 2A2) and one
antagonist (1F8).
Later this set was extended to the full set of compounds from the paper by
Sadowsky et al. [91], which are based on the same scaffold as 2A2 and JS30,
and are detailed in Tables 3.1 and 3.2. For these further compounds, no crys-
tal structures were available, and so modifications to the ligand structures
were made using 3ORZ and 3OTU as a template.
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3.2.1.2 Protein preparation
Crystal structures were found in the PDB database, which were provided
by Sadowsky et al. [91] for three systems. Two of these are of PDK1 bound
to two different activating molecules: 3ORZ (ligand 2A2) and 3OTU (lig-
and JS30), and one bound to an inhibitor 3ORX (ligand 1F8). Experimen-
tal assays used a construct that contained residues 51–359 of the full wild
type, so representing the catalytic domain of PDK1. Hence it would be
ideal to model the same sequence which was used experimentally. In all
cases, parts of the protein were missing; namely the activation loop (3ORX
missing residue 237; 3ORZ missing residues 232-240; and 3OTU missing
residues 232-236), and a section of the N-terminal region (3ORX missing
residue 51-74; 3ORZ missing residues 51-73; and 3OTU missing residues
51-76). Model structures of PDK1 were set up for three systems (for ligands
2A2, JS30 and 1F8) using the software MODELLER [100]. The first mod-
els which were set up included the amino-acid sequence used in the kinase
activity assay (residues 51-359 of the full wild type), meaning that part of
the activation loop and part of the N-terminal region were modelled using
the "automodel" function of MODELLER. Further models were constructed,
again using the same method as above, but using a shorter amino acid se-
quence to remove this N-terminal region (removing residues 51-74). The
model protein which was used for the apo-PDK1 was based on the crys-
tal structure provided for the inhibited system, 3ORX. In all cases, crystal
waters and ions were removed, and the protein structure was prepared us-
ing Maestro [101]: missing hydrogen atoms were added, and N-methyl and
acetyl groups were added to the C and N terminal ends of the protein re-
spectively.
3.2.1.3 Substrate peptide
The work from Sadowsky [91] provided activity data based on phospho-
rylation of a peptide substrate, which had been derived from the activa-
tion loop of a PDK1 substrate, Akt, with one mutation of a cysteine to ala-
nine, in order to improve solubility. The full sequence of the peptide used
3.2. Methods 51
was KTFAGTPEYLAPEVRR, however for our simulation protocol this pep-
tide was truncated, and modelled as an hexapeptide (KTFAGT) with an N-
methyl amine group capping the C terminal end. This sequence seems suf-
ficient, as when considering substrates of PDK1, these residues represent
the most conserved part of the set of substrates (figure 3.9). Modelling the
entire peptide would likely require longer simulation time, and increase the
likeliness of incorrectly predicting the binding mode.
FIGURE 3.9: Substrate peptide from Sadowsky paper, com-
pared to activation loop of kinase substrates of PDK1. Colours
represent residues which are most conserved across the set.
The peptide binding mode was predicted using the software Pepsite
[102] as no crystal structure exists for the peptide used in the activity assay,
or of PDK1 bound to a substrate kinase. Predicted structures were only rea-
sonable when using the conformation of the protein from crystal structure
with activator bound (3ORZ); and no reasonable predictions were obtained
when using the inhibitor bound structure (3ORX). Reasonable predictions
were determined by considering the distance of the γ-phosphate of ATP to
the threonine of the peptide, as this is the residue which the phosphate from
ATP would be transferred to.
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3.2.1.4 ATP
The crystal structure which is being used to set up the model of PDK1 [91]
has an ATP competitive ligand bound in the orthosteric site, rather than
ATP. Therefore in order to obtain coordinates for ATP bound at this site,
other crystal structures were used: PDB ID 4AW0 for the inhibited complex
[103] , and PDB ID 4A07 for the activated complex [104] . The parameters
and structure used for ATP were taken from work carried out by Meagher
et al. [105].
3.2.1.5 Magnesium ions
Two magnesium ions are also located in the orthosteric site of PDK1, which
are important in catalysing the transfer of a phosphate from ATP to the sub-
strate protein. In the crystal structures provided by Sadowsky et al. [91],
no magnesium ions are present in the binding site. Therefore coordinates
for the two Mg2+ ions were also taken from crystal structures 4AW0 and
4A07. Several types of models for metal ions have been employed for pro-
tein simulations, which traditionally involved a spherical ion which is either
bound [106] or unbound [107, 108] to the surrounding protein residues and
ATP. More recent models are based on work by Aqvist [109] and attempt to
better allow for changes in coordination during the simulation. To achieve
this, is is possible to implement a "dummy model", where particles with par-
tial charges (dummy atoms) are placed around the central metal ion, in the
usual coordination for a particular metal ion. For the two Mg2+ ions in the
orthosteric site of PDK1, parameters provided by Kamerlin et al. were used
[110, 111] and converted for use with Amber, which describe an octahedral
dummy model (Figure 3.10). A δ+ charge is applied to each dummy atom,
which must sum to the overall charge of the metal (2+ for magnesium), and
the central metal has (n − 6δ) charge (where n is the charge of the metal).
Dummy atoms are bound to the metal centre, however no bonds are created
between the dummy atoms and surrounding ligands, therefore changes in
coordination during the simulation are possible. This model also shows im-
provement when two ions are in close proximity to one another, as with the
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FIGURE 3.10: Octahedral dummy model for Mg2+ ion. Cen-
tral green sphere is Mg ion and grey spheres are point charges
arranged in octahedral geometry around central Mg.
non-bonded spherical model there can be issues with repulsion between the
ions, which the dummy model should overcome. As the PDK1 system has
two Mg2+ ions located close to one another within the ATP binding site,
this model should show improvement over the previously used spherical
model.
Placement of water molecules within the ATP binding site seems to be
important, as distortions in both geometry of ATP and nearby residues oc-
cur if the Mg2+ ions are not sufficiently solvated prior to equilibration, to
allow formation of an octahedral geometry. In other kinases, crystal struc-
tures with resolved water molecules in this site (PDB ID 1YTM (3 water
molecules) and 1I59 (2 water molecules) show Mg2+ with octahedral geom-
etry, as expected, with each Mg2+ interacting with oxygen phosphates of
ATP, and with nearby residues and with either 2 or 3 water molecules. Two
sets of simulations were initially set up, for PDK1 with inhibiting ligand
1F8: one which took crystal water molecules directly from PDB ID 4AW0,
and another where water molecules were manually placed to allow each
Mg2+ to achieve the octahedral geometry. Both allowed for the expected
Mg2+ water coordination and so all further simulations were set up with
water molecules manually placed at uncoordinated octahedral positions.
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FIGURE 3.11: Structure of PDK1, highlighting ATP and
dummy-model Mg2+ bound at the active site (purple), al-
losteric activator 2A2 bound at the PIF pocket (green), and
substrate peptide (teal) predicted by Pepsite [102].
3.2.1.6 Ligand substrate protein complexes
In each case, a complex was set up as in figure 3.11 including protein, lig-
and, peptide, ATP and Mg2+ ions, using the software ‘leap’ from the Am-
ber14 software package [98]. General Amber Force Field parameters were
assigned to ligand atoms with the addition of the adapted disulphide bond
parameters discussed previously, while the FF14SB-ILDN force field [45]
was used to describe the protein. Phosphate parameters developed by Case
et al. [112] were used to describe the phosphoserine located on the acti-
vation loop of PDK1. Magnesium parameters provided by Kamerlin et al.
were used [110, 111]. Each model complex was then solvated in a box of
TIP3P water molecules extending 10 Å from the edge of the solute, and Cl−
ions added to neutralise the net charge of the complex.
3.2.2 Molecular dynamics simulations
Three protein-ligand systems were initially considered and are referred to
onwards as set A: PDK1 with activator molecule JS30, PDK1 with activa-
tor molecule 2A2, and PDK1 with inhibitor 1F8 (structures highlighted in
3.2. Methods 55
Figure 3.16 and Table 3.1). Also simulations of PDK1 without allosteric lig-
and bound were included in this set, allowing differences between bound
and unbound proteins to be assessed. For the non-ligand bound simulation,
the structure modelled from 3ORX was used for the protein. Later the set
of simulations was extended to include further compounds, referred to as
set B, and include compounds from the same scaffolds as JS30 and 2A2. Fi-
nally, simulations were run for the full compound set, and each set is shown
in Table 3.2 in section 3.3.
The solvated models were energy minimised using sander, and equili-
brated in NVT conditions using PMEMD (CUDA), from the software pack-
age Amber14 [98]. Energy minimisation using 200 steps of conjugate gra-
dient with restraints on the solute was carried out in order to equilibrate
only the solvent. This was then followed by 4500 steps of conjugate gradi-
ent with no restraints. Equilibration was carried out in the NVT ensemble,
with harmonic Cartesian positional restraints of 10 kcal mol−1 Å−1 initially
on protein, ligand and ATP. Slow heating from 50 K to 300 K was done over
200 ps. Restraints on the protein and the ligand were retained while reduc-
ing those on ATP during the next 450 ps, and finally the restraints on protein
and ligand were slowly reduced to zero (over 2.5 ns). A further 0.5 ns was
run in the NPT ensemble in order to equilbrate solvent density. Equilib-
rium molecular dynamics simulations were run using the software SOMD
(Sire/OpenMM) [56], for a simulation time of 1 µs using a 2 fs timestep and
integration using the Leapfrog Verlet algorithm. Simulation was done in
the NPT ensemble, using the Andersen thermostat [53]. Long range elec-
trostatic interactions were calculated using the reaction field method [49,
113], with a cutoff of 10 Å and a reaction field dielectric constant of 78.3.
Throughout all equilibration and production MD, SHAKE was applied to
constrain all bonds involving hydrogen. In all simulations, snapshots were
saved every 5 ps, resulting in 200k snapshots for every 1 µs simulation.
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3.2.3 Computing distances
Individual distances were initially computed as distributions from each tra-
jectory, to compare the set of simulations using KL or JS divergence. Dis-
tances were calculated using mdtraj [114], and a custom script was devel-
oped to output distributions of a selection of distances of interest. Distances
were selected based on known structural features from the literature, and
distance from the substrate peptide to ATP (see Figure 3.19).
3.2.4 Calculating dihedral angles
Torsional angles have been shown [115] to be a good way to describe cor-
related motions such as those involved in allostery, and could provide a
more generalised approach to understanding allosteric motions, rather than
motions in Cartesian coordinates. Also in the case where visible conforma-
tional changes do not occur, there may be subtle motions involving rotation
around torsional angles, which are responsible for the activity, which may
otherwise not be apparent. These analysis scripts calculate distributions of
ψ, φ, χ1 and χ2, which are highlighted in figure 3.12.
3.2.4.1 KL divergence: dihedral angles
To compute KL divergence of torsional angles, a script was developed which
utilises mdtraj [114], and calculates distributions for each ψ , φ, χ1 and χ2
angle. For each angle, a fixed value is then split over all empty histogram
bins, and a file saved with the histogram data for each angle. This is then
computed for each ligand bound simulation, and again for the simulation
with no ligand bound. Another script then calculates the KL divergence be-
tween any two simulations, and gives a KL value per angle. This is summed
into "backbone" (ψ + φ) and "sidechain" (χ1 + χ2). Six identical PDB struc-
tures are then edited: four for the individual torsions (ψ , φ, χ1 and χ2); and
then two for the summed backbone and sidechain. For each the KL value is
input into the B-factor column of the PDB file. These are then loaded into
Pymol [99] for visualisation. A flowchart of this process can be seen in figure
3.13.
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FIGURE 3.12: Torsional angles calculated illustrated on a ty-
rosine residue. Angles φ and ψ are backbone torsions, and χ1
and χ2 are the first and second sidechain torsions.
3.2.5 PCA
PCA was initially applied to a combination of four trajectories (3ORX, 3ORZ,
3OTU and APO) using the PyEMMA software [116], selecting only Cα co-
ordinates as input dimensions. Component loadings were computed which
gave a value of how much of the variance comes from a particular atom.
These loadings were then visualised by inputting this value as a B-factor,
and visualised using a colour scale using PyMOL to highlight motion in-
volved in each mode[99]. Structures corresponding to the maximum and
minimum values for PC1 and PC2 were output for each system. In addition,
the value per snapshot, and the distribution of PC1 and PC2 were obtained
for each input system.
PCA was later extended to include sets B and C, shown in 3.2. Distribu-
tions of PC1 were output for each system, and JS divergence computed for
each compound pair. JS values were then clustered as described in 3.2.8.
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FIGURE 3.13: Calculation of dihedral KL.
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3.2.6 Energy decomposition
Interaction energies were computed as described in section 2.4. Values are
calculated for both the Lennard-Jones and Coulombic contributions at each
timestep. These values can then be summed across a range of residues to
give overall interaction energy profiles as probability distributions, for ex-
ample for a ligand with the entire protein.
3.2.7 MI calculation
MI based on various descriptors was computed with three different python
scripts: two were available or adapted from scikit [117, 118], and the third
was an in house built script. For each descriptor previously calculated
(PCA, distances, interaction energies) a file was saved with the value per
snapshot for the descriptor, and this is given as input to the MI script. Fur-
ther testing was completed with the third MI method ("in-house" script),
using varying numbers of data points and number of bins, to determine
optimal conditions. The process to calculate MI is shown in figure 3.14.
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FIGURE 3.14: Workflow to compute MI between two descrip-
tors.
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3.2.8 Clustering of distance measurements and JS divergence
In order to easily identify similarities/differences between the JS divergence
calculated for various metrics, spectral clustering [119, 120] was performed
using the pyEMMA software [116]. A JS divergence matrix for each simula-
tion pair was constructed, and used to devise a Gaussian diffusion kernel.





In this equation, ε is a cutoff selected based on the structure of the eigen-
values, Mij are the elements of the JS divergence matrix, and K is a measure
of "distances" between two elements i and j. The eigenvalues and eigen-
vectors of a normalised matrix of K define how many clusters the dataset
contains. For example, in figure 3.15, there is a separation in values between
the first and second eigenvector, and so two clusters are selected.
FIGURE 3.15: Eigenvalues for JS divergence values for a par-
ticular distance measured for four different simulations. ε is
selected to maximise the difference in eigenvalues on trial and
error basis. Two states are selected for this example as the
separation in eigenvalues occurs between the first and second
eigenvalue.
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The PCCA algorithm was then applied to assign each simulation to a
particular cluster, and results visualised using a matrix of JS values pre-
sented as a colour scale.
3.2.9 Availability of analysis scripts
Scripts to reproduce the results of this analysis, along with a tutorial using
subsection of the full trajectory used in this thesis, are described in appendix
B, and can be accessed on GitHub [121].
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3.3 Results
Initially, simulations relating to the ligands for which crystal structures were
provided were run and analysed, along with a simulation with no allosteric
ligand. This was later extended to include further compounds in the paper
provided by Sadowsky et al. [91], which were selected to give 4 compounds
from each of scaffold A and B (figure 3.16) and also represent a range of
activities. Later in the project, it was decided to extend this further to the
entire set of compounds based on scaffolds A and B. Therefore, initial results
are presented based on the 3 compound set, the extended 9 compound set,
and then the full 24 compound set.
FIGURE 3.16: Scaffold A and B for allosteric activating ligands
and structure of inhibitor 1F8. R groups shown in table 3.1.
64
Chapter 3. Allosteric modulation of phosphoinositide-dependent
kinase-1 (PDK1) mediated by covalently bound small molecules
Ligand Scaffold R1 R2 R3 R4 R5
JS12 A H H OMe H H
JS26 A H OH H H H
JS28 A Cl Cl H H H
JS10 A Cl H H H H
JS08 A OMe H H H H
JS05 A H H H H H
JS17 A F H H H H
JS16 A Me Me H H H
JS01 A OH H H H H
JS25 A H OMe H H H
JS15 A H H F H H
JS14 A Me H H H H
JS18 A H H Cl H H
2A2* A H Cl H H H
JS19 A H H CF3 H H
JS09 B H -OCH2O- H H
JS04 B Cl H H H Cl
JS02 B H F H H H
JS03 B Cl H Cl H H
JS21 B H Cl Cl H H
JS23 B H Cl H H H
JS24 B H H Cl H H
JS30* B -CH=CH-CH=CH- H H H
TABLE 3.1: R groups for scaffold A and B compounds. *Com-




In all cases, the models obtained using the "automodel" function of the soft-
ware MODELLER [100] showed a good fit to the crystal structures. In partic-
ular the missing loop residues in each case showed a reasonable conforma-
tion based on the adjacent residues which were present in the crystal struc-
ture. In the initial models (residues 51-359), the N-terminal region which
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Set Scaffold Compound Activity +/- Label
Set A
- 1F8 (3ORX) 32 2.2 1
- APO 100 - 2
A 2A2 (3ORZ) 394 9.9 21
B JS30 (3OTU) 630 15 25
Set B
A JS10 210 18 6
A JS18 370 32 18
A JS19 510 48 24
B JS09 240 22 9
B JS04 330 31 16
B JS23 460 39 22
Set C
A JS12 160 21 3
A JS26 170 15 4
A JS28 200 20 5
A JS08 220 20 7
A JS05 220 18 8
A JS17 240 22 10
A JS16 240 22 11
A JS01 250 23 12
A JS25 260 23 13
A JS15 260 23 14
A JS14 270 24 15
B JS02 340 29 17
B JS03 380 32 19
B JS21 390 33 20
B JS24 460 73 23
TABLE 3.2: Full compound set with activities as percentage
relative to apo. Compounds based on scaffolds A and B. La-
bels assigned as numbers in activity order, with compound 1
as inhibitor, and compound 25 as the most activating ligand
JS30.
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was missing from the PDB structure was modelled as an unstructured re-
gion (Figure 3.17 A).
FIGURE 3.17: A) Initial model generated with sequence
matching that used in the experimental assay by Sadowsky
et al. [91] containing residues 51–359 of the full wild type. B)
Shortened model used for all simulations using only residues
75-359 of the full wild type.
This extended out from the protein, and was deemed problematic for
follow up MD simulations, as a much larger water box must be used to
solvate. Furthermore, the significant flexibility of this N-terminal segment
could pose sampling challenges. The main factor to consider when deciding
the length of chain to model is whether this will have an effect on activity.
This N-terminal region does not seem close enough in space to the active
sites to interact. In addition, it is impossible to determine the accuracy of
this part of the model, and no related crystal structures exist for this region.
It is therefore sensible to omit this from further models given the difficulties
this may cause with the simulation, when this modelled region may not
even realistic, and so a shorter model consisting of residues 75-359 (with
acetyl group added to residue 75 and N-methyl group added to residue
359), will be used to run simulations (Figure 3.17 B).
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All further numbering of residues uses the first residue of the model as
residue number 1.
3.3.1.2 Peptide
Peptide conformations predicted by Pepsite [102] seem to give reasonable
results. As there are no structures of PDK1 with this peptide, or with sub-
strate protein bound, related kinase structures are used to validate the re-
sults. Two related kinases were found which have available structures with
active site peptide inhibitors. Protein kinase A (cAMP-dependent protein
kinase) and protein kinase B (Akt) are both part of the same family of pro-
tein kianses as PDK1 (AGC kinases), and comparison of the predicted Pep-
site conformation with crystal structures 1ATP and 3CQU suggests that the
predicted conformation is reasonable as the predicted pose is close to these
crystal strucutres, and allows the Thr of the peptide to be reasonably close
to ATP, as seen in figure 3.18.
3.3.2 Distributions of distances relating to reaction mecha-
nism
The initial analysis completed calculated distances between residues which
are known in the literature to vary between activated and inhibited struc-
tures, and in addition the distance between ATP and the substrate. The
distances computed are highlighted in figure 3.19.
3.3.2.1 ATP γ-phosphate to substrate Peptide-Thr distance
To determine whether particular structural changes influence the rate of
phosphorylation, it is important to relate changes in the protein structure
to some measurement which corresponds with substrate phosphorylation.
Any of three distinct steps could be rate limiting during this process: sub-
strate binding, phosphate transfer, or product release. Studies of PDK1 have
shown that the phosphate transfer seems to be rate limiting [122], however,
inhibition or activation by an allosteric ligand could, in theory, alter the rate
of any of these three steps. Yet, for phosphorylation to occur, the substrate
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FIGURE 3.18: Predicted conformation of peptide using Pep-
site [102] in purple. Crystal structure 3CQU in grey. Crystal
structure 1ATP in teal.
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FIGURE 3.19: Distances computed based on information avail-
able in the literature. Distances calculated for Lys39(N) to
Glu58(C); Tyr54(O) to ATP(γ-Phos); and substrate Thr(O) to
ATP(γ-Phos).
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APO 3.33 3.83 0.43 0.00
1F8 (Inhibitor) 3.33 9.52 0.95 7.18
2A2 (Activator) 3.33 5.36 1.12 1.33
JS30 (Activator) 3.33 3.47 0.14 1.76
TABLE 3.3: Distances for peptide-Thr to γ-phosphate of ATP.
must bind such that the Thr residue which will be phosphorylated comes
into reasonably close contact with the γ-phosphate of ATP, and as the phos-
phate transfer step is the rate limiting step, this could be monitored for dif-
ferent allosteric activator and inhibitor simulations. There are two poten-
tial mechanisms for phosphate transfer [123, 124], either via associative or
dissociative pathways (figure 3.20). In both scenarios, the γ-phosphate of
ATP must be within a reasonable distance (a few Å) to the substrate pep-
tide threonine (Pep-Thr) for the reaction to proceed. Therefore it would be
useful to see differences between activated and inhibited complexes, in the
distance from the Pep-Thr, to the phosphate of ATP which will be trans-
ferred. Starting from the same peptide conformation with identical ATP to
Pep-Thr distance, this was measured for the full 1 µs trajectory, and the re-
sults are shown in table 3.3 and figure 3.21. This shows that with the most
activating compound (JS30), distances remained consistently at reasonably
short distances, which would allow transfer of a phosphate. With activator
2A2, these distances were slightly longer, however reasonably long sections
of the trajectory are at distances short enough for phosphate transfer to oc-
cur. For the inhibitor simulation, within around 200 ns, the peptide Thr is
too far from the ATP site, and average distances are above 9 Å.
To validate these results, repeat runs of 100 ns were completed for the
apo, inhibitor bound, and one activator bound (2A2) simulations. Results
are in table 3.4 and highlight that in all cases, the values for the activator
bound are shorter than inhibitor bound. It also highlights that both the acti-
vator and inhibitor bound have only small variations in the values between
runs, with standard deviations of 0.16 Å and 0.67 Å respectively. However
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FIGURE 3.20: Phosphorylation of substrate kinase at serine,
threonine, tyrosine, or histidine could occur via associative
(SN2-like: left) or dissociative (SN1-like: right) mechanisms.
Figure adapted from reference [124].
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FIGURE 3.21: Distributions of substrate peptide Thr to γ-
phosphate of ATP for the four original simulations completed.
These are based on the 3 crystal structures provided for 3ORX
(inhibitor 1F8), 3ORZ (activator 2A2) and 3OTU (activator
JS30).
with the apo simulation, there is some variation, and standard deviation is
much higher (2.39). This could be consistent with the trend in activity, as
inhibitor bound is consistently at distances too long for catalysis to occur,
activator bound stabilises the peptide close to the active site, and apo gives
shorter distances sometimes, however not as consistently as activator bound.
System Run 1 Run2 Run3 Run4 Run5 Mean σ
APO 6.48 9.71 6.93 4.37 3.63 6.22 2.39
1F8 (Inhibitor) 8.20 6.83 7.74 7.13 8.39 7.66 0.67
2A2 (Activator) 3.58 3.37 3.51 3.55 3.81 3.56 0.16
TABLE 3.4: Average distances for repeat runs. Peptide-Thr to
γ-phosphate of ATP.
The results for the substrate distance for the full compound set can be
found in figure 3.22. In this plot, the orange horizontal line for each com-
pound corresponds to the median, the box represents the lower and upper
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FIGURE 3.22: Distributions of the distance between the γ-
phosphate of ATP and the Thr residue of the peptide which
would be phosphorylated. All simulations are 1 µs.
Compounds numbered as in table 3.2. JS14 is excluded as pep-
tide dissociates from the active site in this simulation.
quartiles, and the "whiskers" (lines extending from each box) represent val-
ues at 5th and 95th percentile, and "x" marks the minimum and maximum
values. From these distributions, the inhibitor bound simulation has the
majority of distances above 7.5 Å. In most cases with activator bound, al-
though some of the distribution lies at longer distances, there is significant
probability at values short enough for phosphate transfer to occur. In the
highest activating compounds (i.e. compounds 15-24 in figure 3.22), there is
a much higher percentage of snapshots at shorter distances.
From figure 3.21, it is clear that the inhibitor bound simulation shows
different behaviour, however this is more difficult to analyse when dealing
with large sets of compounds. In order to more easily compare these dis-
tributions, the JS divergence was computed for each pair of compounds.
In figure 3.23, the JS divergence for each of the four original simulations is
shown. Darker colours represent higher JS divergence, and so larger vari-
ations between the distributions. White represents a JS divergence of zero,
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and hence diagonal values are white, as JSD(P ‖ P) = 0.
FIGURE 3.23: JS divergence for original four compound set of
ATP-Peptide distance distributions. Clustering described in
section 3.2.8, using ε=0.1 with 2 states.
This shows clearly that inhibitor 1F8 has the largest differences to any
other compounds in this set, where JS divergence values when comparing
1F8 to every other simulation are around values of 0.6 or above.
This was then extended to the full set of compounds, and shown in fig-
ure 3.24. The results for this show some indication of a trend, with the high-
est activating compounds showing the most similarity.
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FIGURE 3.24: JS divergence for ATP-Peptide distance distribu-
tions. Clustering described in section 3.2.8, using ε=0.2 with 3
states.
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3.3.2.2 Lys39 to Glu58 distance: a salt bridge between the active and al-
losteric sites.
In a study by Engel et al. [125], it was suggested that activation of PDK1
must involve a conformational change, which they state involves motion of
the α-helix C, which is located between the PIF pocket and the ATP bind-
ing site (see Figure 3.1 and Figure 3.11). Movement of this helix results in
motion of Glu58 (located on the helix), which in turn affects the position
of another residue, Lys39, to interact with the phosphates of ATP. The dis-
tance between these two residues was measured by the distance between
the sidechain N atom of lysine, and the terminal sidechain C atom of glu-
tamic acid.
FIGURE 3.25: Distributions of the Lys39-Glu58 distance for the
original set of simulations. Activator JS30 (3OTU), activator
2A2 (3ORZ), inhibitor 1F8 (3ORX) and with no allosteric lig-
and bound (APO).
A set of values for this distance was obtained over the course of the sim-
ulation, and the data plotted as a histogram (Figure 3.25). Average distances
and standard deviations, along with KL divergence were computed and val-
ues are also summarised in table 3.5. Compounds 1F8 and JS30 show the
largest differences in activity to Apo-PDK1, being the most inhibiting and
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most activating ligands respectively. These two ligands also show the high-
est KL relative to Apo for this distance, which is consistent with the trend in
activity. Compound 2A2 is also activating, but shows less change in activity









APO 3.30 3.56 0.34 0.00
1F8 (Inhibitor) 3.62 5.26 0.77 2.58
2A2 (Activator) 4.05 4.13 0.49 1.30
JS30 (Activator) 3.86 4.25 0.36 3.31
TABLE 3.5: Distances from N of Lys39 to C of Glu58.
However when this was extended to the full set of compounds, the result
is less clear. There is no clear trend related to activity, as shown in figure
3.26.
FIGURE 3.26: Distributions of the distance between Lys39 and
Glu58. Compounds numbered as in table 3.2.
As with the previous distance computed, a matrix was first constructed
for JS divergence values using the original set of four compounds, and can
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FIGURE 3.27: JS divergence for original four compound set of
Glu-Lys distance distributions. Clustering described in section
3.2.8, using ε=0.2 with 2 states.
be seen in figure 3.27. This indicated similarity between the two activators,
and showed that inhibitor 1F8 and apo were different to the two activators,
but also different to each other. This was then extended to the full set, and it
is clear that there seems to be no trend in these values based on activity for
the full set of activators (figure 3.28), however some compounds show more
similar behaviour to each other than to others.
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FIGURE 3.28: JS divergence for Glu-Lys distance distributions.
Clustering described in section 3.2.8, using ε=0.1 with 4 states.
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3.3.2.3 Tyr54 to ATP distance varies between activated and inhibited con-
formations.
Differences in the position of Tyr54 can be seen between activated and in-
hibited crystal structures (figure 3.29). In activated complexes, visual in-
spection of the X-ray structures suggests that the hydroxyl group of Tyr54
is close enough to ATP to form hydrogen bonds with γ-phosphate of ATP.
In the inhibited complex, this side chain flips away and no H-bonding is
possible.
This distance was monitored for 1 µs of simulation, and in the inhibited
complex this distance remained in one distribution of values variation dur-
ing the simulation, at relatively long distances, between 12 and 23 Å (Figure
3.30).
However with either of the two activators bound this group seems to be
much more dynamic, and both have significant amount of the distribution
as shorter distances (figure 3.30) than the inhibited complex. By comparison
of the distribution of these values using KL divergence, it can be seen that
relative to PDK1 with no allosteric effector, inhibitor bound PDK1 shows
the largest KL value compared to the two activators (table 3.6). Differences
in how residues interact with ATP could be key to explaining differences in
activity, since stabilisation by hydrogen bonding of the phosphates of ATP
could facilitate phosphate transfer. It is also important to highlight the shift
to shorter values for the Apo simulation. As the starting structure for this
simulation was the same as that for the inhibitor bound, the inhibitor does










APO 15.89 13.08 2.99 0.00
1F8 (Inhibitor) 15.89 16.81 1.23 5.80
2A2 (Activator) 5.58 13.70 5.28 1.32
JS30 (Activator) 5.80 12.73 2.64 1.43
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FIGURE 3.30: Distributions of Tyr54 (O(H)) to γ-phosphate (P)
of ATP for the four original simulations completed. These are
based on the 3 crystal structures provided for 3ORX (inhibitor
1F8), 3ORZ (activator 2A2) and 3OTU (activator JS30).
This was then extended to the full set, and results summarised in figure
3.31. This shows that only the inhibitor bound simulation has the majority
of the distribution above distances of around 15 Å.
The JS divergence matrix on the original set of four compounds high-
lights the largest difference between the most activating, and most inhibit-
ing ligands (figure 3.32).
Extended to the full set, some differences can be seen. The inhibitor
bound (1F8) shows large differences with almost all of the set, while all acti-
vators show lower JS values with at least a subset of activators. There does
not seem to be a trend relating to either the amount of activation or the scaf-
fold. Some compounds show similar behaviour and have similar activities,
such as JS26, JS10, JS08, JS17 and JS16, which all have activities in the range
170-240 % relative to apo.
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FIGURE 3.31: Distributions of the distance between the γ-
phosphate of ATP and Tyr54. Compounds numbered as in
table 3.2.
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FIGURE 3.32: JS divergence for original four compound set
of Tyr54-ATP distance distributions. Clustering described in
section 3.2.8, using ε=0.2 with 2 states.
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FIGURE 3.33: JS divergence for Tyr-ATP distance distribu-
tions. Clustering described in section 3.2.8, using ε=0.15 with
5 states.
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All distance analysis has also been completed for a set of two "swapped
ligand" simulations, where activator JS30 and inhibitor 1F8 were modelled
into structures 3ORX and 3OTU respectively. Results are found later in sec-
tion 3.3.7.
3.3.3 Torsion KL
The distances previously calculated rely on some structural knowledge of
the system under study. However it is useful to ensure that analysis carried
out is not biased, and therefore require methods which do not rely on any
prior knowledge. The first method used to carry out a more unbiased analy-
sis is to compute distributions of all torsional angles, and use KL divergence
to compare between the activated and inhibited systems.
3.3.3.1 KL testing
Testing was carried out by changing the prior count added to each bin. As
mentioned in section 2.3.1, equation 2.19 describes addition of a uniform
prior count to all bins. The factor of x determines the value used for the prior
count, as a fraction of the mean value is added into each bin before distribut-










106 were tried initially.
For two distributions which are almost continuous (for example, from two
different simulations of the same system), the KL value obtained converges
using a value of x of 1103 , or smaller. However in the case of a poor overlap
of distributions, this has a more pronounced effect, and difficulties could
therefore arise if comparing two KL values; where one is obtained for two
well overlapping distributions and the other is for two poorly overlapping
distributions, and so the result is not consistent. There are various methods
which can be used to solve this. In this case, a fixed value was split over
all zero-valued bins only, rather than a uniform amount being added to all
bins. In this way, the amount added to an empty bin is effectively weighted
depending on the extent of the overlap between two distributions.
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Further testing was completed to determine if the KL values obtained
were due to differences between the systems, or an artefact of finite sam-
pling. To achieve this, a single trajectory was split into 4 segments, and the
KL divergence computed between the different segments of the same sim-
ulation. For each trial completed in this way, the KL values were negligible
when compared to the KL values obtained by comparing two systems.
3.3.3.2 KL on original compound set
Analysis is carried out by computing distributions of ψ, φ, χ1 and χ2 angles.
For each angle, this is plotted as a normalised histogram for four different
systems: PDK1 only, PDK1 with activating ligand JS30 (3OTU), PDK1 with
activating ligand 2A2 (3ORZ) and PDK1 with inhibiting ligand 1F8 (3ORX).
The KL values obtained were then visualised as Cα "B-factor" using the
software PyMol [99]. This allowed simple identification of areas where tor-
sional angles differed the most between activated and inhibited systems
and results are also shown for summed "backbone" (ψ + φ) and "sidechain"
(χ1 + χ2) KL values. The largest differences in backbone torsions between
activating ligand JS30 (PDB ID 3OTU) and inhibiting ligand 1F8 (PDB ID
3ORX) highlighted several residues around the hinge of the activation loop
(3.34). Results are similar when comparing another activator 2A2 (PDB ID
3ORZ) to the same inhibitor 1F8 (PDB ID 3ORX) as shown in figure 3.35.
Differences in side chains were closer to the ATP binding site and included
residues in the functionally relevant DFG-loop. Again, similar regions are
highlighted when comparing activating ligand 2A2 (3ORZ) to the same in-
hibitor.
88
Chapter 3. Allosteric modulation of phosphoinositide-dependent
kinase-1 (PDK1) mediated by covalently bound small molecules
FIGURE 3.34: KL-divergence for A: backbone and B: sidechain
torsional angles for KL(JS30|1F8).
3.3. Results 89
FIGURE 3.35: KL-divergence for A: backbone and B: sidechain
torsional angles for KL(2A2|1F8).
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3.3.4 PCA on Cα coordinates
3.3.4.1 Initial compound set
Initial analysis included only the four simulations from Set A as in table 3.2:
ligands 1F8, 2A2, JS30 and with no allosteric ligand. The first and second
eigenvectors correspond to 26 % and 20 % of the variance respectively. PC1
coresponds to the activation loop motion, which contributes to the largest
percentage of variance due to differences between activated and inhibited
complexes. Per atom contributions to PC1 were visualised as per figure
3.36A. The highest atom contribution to PC1 is the residues of the activation
loop (residues Ser159-Asn168).
FIGURE 3.36: PC1 of four simulations: Yellow: activator JS30;
Blue: activator 2A2; Green: apo; Red: inhibitor 1F8. A: Per
residue contribution to PC1. Colour scheme is white-grey-red
with increasing contribution. B: Distributions of PC1 for each
system. C1-C4: structures corresponding to minimum (grey)
and maximum (colour) values of PC1.
With either of the two activating compounds bound (JS30 and 2A2), this
loop visits a wider range of conformations than with inhibitor bound (1F8),
this can be seen by considering the distributions in figure 3.36B. Structures
3.3. Results 91
representing the maximum and minimum values for PC1 for each system
are shown in figure 3.36C.
PC1 results are in line with previously discussed Kullback-Leibler (KL)
diversion results in section 3.3.3 between activated and inhibited systems
using backbone torsional angles, which also highlighted that the highest
differences were found in a hinge region of the activation loop (figures 3.34A
and 3.35A).
As discussed in section 3.3.2.3, a notable difference between activator
and inhibitor bound simulations is in the conformation of Tyr54. The dis-
tance from Tyr54 to ATP for both activators, and the apo simulations is
shorter, but they also have a wider range of values than for inhibitor bound.
This could affect the conformation of the activation loop. In the inhibitor
bound simulation, Tyr54 is flipped away from ATP, and makes an interac-
tion with the phosphoserine on the activation loop (figure 3.29). In the ac-
tivator bound simulations, Tyr54 adpots both conformations: towards ATP,
and flipped away. In the inhibitor bound this interaction seems more sta-
ble, which could restrict the motion of the loop. The more dynamic con-
formation of Tyr54 in the activator bound simulations could allow for the
loop conformations corresponding to the maximum PC1 values, which are
shown in figure 3.36.
The result is that in simulations with allosteric inhibitor or with no al-
losteric ligand, the variance of this loop motion is substantially less than
for either of the two activators. Distributions of these values highlight this,
with only the two activators having values at the higher range of PC1 (figure
3.36B).
The results for PC2 show that all allosteric ligand bound simulations
have a shift in the distribution of PC2 relative to apo, as shown in figure
3.37B, but there doesn’t seem to be similarity between the two activators.
Per atom contributions to PC2 show that this predominantly involves the
residues of helix-B, and β strands 1 and 2.
Plots of PC1 and PC2 values per snapshot, and a two-dimensional plot
of PC1 and PC2 with each trajectory overlaid, can be found in the appendix
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FIGURE 3.37: PC2 of four simulations: Yellow: activator JS30;
Blue: activator 2A2; Green: apo; Red: inhibitor 1F8. A: Per
atom contribution to PC2. B: Distributions of PC2 for each
system. C1-C4: structures corresponding to minimum (grey)
and maximum (colour) values of PC2.
3.3.4.2 Extended compound set
PCA was then extended to include further ligands from the set for which ac-
tivity data is provided by Sadowsky et al. [91]. Compounds were selected
to cover a range of activities, from both scaffold A and scaffold B (which
are the scaffolds for the two crystal structures 3ORZ and 3OTU). The com-
pounds selected can be seen in table 3.2, and this analysis includes set A and
B from this table.
Again this highlighted activation loop motion as the first principal com-
ponent, which describes 26% of the variance in the dataset. Compounds
were then separated based on activity, and this highlighted the differences
between the inhibitor bound and activator bound simulations. Only the
highest activating compounds shown in figure 3.38(C) show values for PC1
higher than 1.5. These values of PC1 correspond the the conformation of the
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loop shown in 3.38(C) in grey, where the activation loop moves much closer
to alpha helix C. Based on this subset of data, it appeared that the highest
activating compounds all share a conformation not accessed by the lower
activating, or inhibiting ligand bound simulations. As the helix C is located
between the allosteric and active sites, and the loop interacts with this helix
at Tyr54, is is possible that the allosteric ligands affect the helix C, which in
turn affects the loop position, and this has some influence on the activity.
The position of the loop can affect the substrate binding, as this binds near
to the the γ-phosphate of ATP, which is near the hinge region of the loop as
seen in figure 3.11.
From these distributions, the structures corresponding to the positive
values of PC1 which show the highest population for each system were out-
put, and can be seen in figure 3.39. This shows that the loop is closer to
α-helix C in both cases. For the inhibitor and apo simulations, the loop is
much further from α-helix C.
It can then be seen that the α-helix C position varies in the structures
where the activation loop is closer to α-helix C. A closer look at the position
of this helix shows that in the apo and inhibitor bound conformations, the
helix is much closer to the allosteric site. However when inhibitor is bound,
this moves closer to the active site, as in figure 3.40.
This helix contains Glu58, previously discussed in section 3.3.2.2, which
forms a salt bridge with Lys39. Comparing the inhibited structure to the
two highest activators, it seems that the interactions with ATP are increased
as the helix moves closer to the active site, with the activating compounds,
shown in figure 3.41.
In order to attempt to validate this trend, JS divergence values were com-
puted using the distributions of PC1 for this compound set. The results were
clustered, and summarised in figure 3.42.
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FIGURE 3.38: PC1 for extended compound set. A: Per atom
contribution to PC1. Colour scale White-Grey-Orange-Red
with increasing KL value. B: structures representing maxi-
mum and minimum PC1 values for B1: JS30; B2: JS10; and B3:
1F8. C: Distributions for PC1. Compounds separated based
on activity with C1: highest activators; C2: medium activa-
tors; and C3: apo and inhibitor.
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FIGURE 3.39: Conformations representing the high values of
PC1 at the most populated point of each distribution for JS19
(purple) JS30 (lilac) 1F8 (red) and apo (green). Highlighted
regions are the activation loop and helix C. The allosteric site
is on the left, with ATP bound at the central active site, and
both are shown in sticks.
FIGURE 3.40: Helix C for JS19 (purple), JS30 (lilac), 1F8 (red)
and apo (green). Allosteric ligand JS30 is shown on the right,
and ATP bound at the active site is shown on the left.
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FIGURE 3.41: Helix C with Glu58 for JS19(510-purple),
JS30(630-lilac) and 1F8(inhibitor-red). Allosteric ligand JS30
is shown below helix C, and ATP bound at the active site is
shown on the top left.
The second principal component highlights many residues around the
allosteric site, in particular the smaller α-helix B adjacent to α-helix C. The
difference in position of helix B, could affect the position of helix C, and
so could also contribute to the difference between the active and inhibited
conformation. As compounds based on scaffold B are longer than scaffold
A due to the extra CH2, they sit further towards this smaller helix and could
cause this shift.
Therefore, distributions for PC2 were plotted, and separated based on
scaffold. With the exception of compound JS09, there seems to be separation
of PC2 based on scaffold. JS09 could be an outlier, as the structure has a
fused ring to R2 and R3 (see figure 3.16 and table 3.1), which points directly
towards this smaller helix (α-B).
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FIGURE 3.42: JS divergence for extended compounds set of
PC1 distributions. Clustering described in section 3.2.8, using
ε=0.2 with 3 states.
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FIGURE 3.43: PC2 for extended compound set. A: Per atom
contribution to PC2. Colour scale White-Grey-Orange-Red
with increasing KL value. B: structures representing maxi-
mum and minimum PC2 values for B1: JS30; B2: JS10; and B3:
1F8. C: Distributions for PC2. Compounds separated based
on scaffold with C1: scaffold B; C2: scaffold A; and C3: apo
and inhibitor.
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3.3.4.3 Full compound set for scaffold A and B
The full set of compounds based on scaffold A and B can be seen in table
3.2, and PCA results discussed so far only included a subset of these com-
pounds. In order to attempt to validate the results, PCA was run for the full
set of simulations. The first and second principal components are very sim-
ilar to that obtained for the previous sets of compounds. However, now the
full set of compounds has many more compounds of similar activities. The
results highlight that the trend noticed for the previous set of compounds
does not extend to the full set. The inhibitor still shows different behaviour
to any of the activating set, however it is not possible to determine the de-
gree of activation as some of the lower activating compounds show the same
PC1 distributions as high activating compounds. To highlight any differ-
ences, the JS divergence of PC1 was clustered as shown in figure 3.44.
Results for PC2 also are not entirely clear however do show some sepa-
ration of scaffold A and B compounds.
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FIGURE 3.44: JS divergence for full compound set on PC1.
Compounds numbered as in table 3.2. Clustering described
in section 3.2.8, using ε=0.07 with 3 states.
3.3. Results 101
FIGURE 3.45: JS divergence for full compound set on PC2.
Compounds numbered as in table 3.2. Clustering described
in section 3.2.8, using ε=0.05 with 4 states.
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3.3.5 Energy decomposition
The geometric descriptors previously discussed are useful in determining
differences between activated and inhibited conformations, however this
does not directly confirm trends in activity. Many of these measurements
are based on information which can be obtained from the crystal structure,
or knowledge of the system under study, and so require advance knowl-
edge of the differences between active and inhibited complexes. Other dif-
ferences (e.g. PCA) show structural differences but do not confirm if these
are important for activity as they cannot directly correlate the high variance
motions with a functionally relevant descriptor. One potential way to high-
light important structural changes without this bias, is to compute interac-
tion energies between various residues. This allows easier identification of
which structural changes could be related to changes in activity. This can
be achieved by decomposing the potential energy surface into per residue
interactions, allowing identification of which residues are responsible for
binding, or alternatively which are blocking access to ligand/substrate via
repulsive interactions. Also important to understand is the structure-activity
relationship of the ligands bound to the allosteric site. By computing inter-
actions of the allosteric ligand with the protein, it may be possible to explain
differences in activity. Energy analysis was computed for various residues,
and also for all residues in the peptide which could then be summed to
give overall interaction energies of the peptide with the protein/ATP. All
energies quoted are a sum of the Coulombic and Lennard Jones interaction
energies.
3.3.5.1 Peptide interactions
Interactions of the peptide were computed, in order to attempt to highlight
any differences that may affect substrate access to ATP. Summing all protein
residue interactions with the peptide show that for both activator bound
and inhibitor bound simulations, the overall peptide-protein interactions
are attractive and show no particular trend. Results can be seen in table 3.7.
The differences in how the peptide interacts when comparing activators to
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Ligand Peptide PepThr ATP ATP
Ligand Protein Protein Pep-Thr Entire peptide
1JS10 -120.71 -3.59 -16.36 -168.92
2JS18 -97.83 -7.9 -21.83 -184.22
3JS19 -133.74 -13.96 -32.17 -187.62
1JS09 -100.62 -13.54 -24.02 -233.65
2JS04 -138.96 -10.02 -28.08 -161.29
3JS23 -104.38 -7.94 -25.02 -230.19
1F8 -122.5 -23.9 2.94 -214.65
APO -118.1 -0.93 -39.45 -215.8
2A2 -125.84 -12.25 -24.44 36.11
JS30 -23.7 -0.68 -20.24 -158.91
TABLE 3.7: Interaction energies of the substrate peptide with
different parts of the system. Peptide-protein interactions;
peptide Thr residue with protein interactions; ATP with pep-
tide Thr; and ATP with the entire peptide.
Energies in kcal mol−1
.
the inhibitor is only in the peptide Thr residue and the interactions of this
residue with ATP.
To further understand how the interactions vary, the interaction of the
peptide with each residue of the protein was input as a B-factor and vi-
sualised, where residues highlighted in blue are attractive interactions and
residues shown in red are repulsive, as shown in figure 3.46. This shows
that with inhibitor 1F8 bound, the interactions around ATP do seem to vary
when compared to activator 2A2; and that particularly the repulsive inter-
action of Lys39 could result in differences in positioning of the substrate.
3.3.5.2 Allosteric ligand
Interactions of the allosteric ligand with the protein could help to iden-
tify the differences in ligand structure which lead to differences in func-
tion. The most notable difference in interactions between activating ligand
2A2 (2ORZ) and inhibiting ligand 1F8 (3ORX) was with Arg59 (figure 3.47).
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FIGURE 3.46: Interaction energies of the peptide with protein
residues for A: inhibitor 1F8; B: activator 2A2; and C: activator
JS30.
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FIGURE 3.47: Conformation of Arg59 in crystal structures
3OTU (yellow), 3ORZ (blue) and 3ORX (red).
It can be seen from the crystal structure that the side chain adopts differ-
ent conformations in these PDK1-inhibitor and PDK1-activator complexes.
Analysis of the energy interactions suggests that with inhibitor bound, there
are larger attractive interactions with this residue and potentially this could
result in the rotation of helix αC. Adjacent to Arg59, Glu58 forms the salt
bridge with Lys39 as previously discussed, and disruption of this interac-
tion changes the interactions with ATP. Therefore if changes in interactions
with Arg59 cause shifts in this helix, this could explain the changes in inter-
actions with ATP.
This residue is also highlighted when calculating the KL divergence of
the interaction energies. Figure 3.48 highlights high KL values in red for
activator 2A2 (3ORZ), calculated relative to inhibitor 1F8 (3ORX). However
activator JS30 (3OTU) does not show this same pattern of interactions yet
still results in shift of helix C in a similar conformation to activator 2A2.
Since JS30 is a bulkier ligand and so taking up more space in the allosteric
pocket, and also shows differences in the interaction energies on the helix
adjacent to C, it is possible that helix C can still adopt the active confor-
mation but without the same interaction pattern. The conformation of the
helix adjacent to helix C could affect the position of helix C, and this could
be sufficient for the change in activity.
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FIGURE 3.48: KL divergence of interaction energies computed
between activator 2A2 and inhibitor 1F8, and between activa-
tor JS30 and inhibitor 1F8.
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3.3.5.3 ATP
Interactions of ATP were computed. As discussed, there is a difference
when inhibitor is bound, in the distance between two residues Lys and Glu
which form a salt bridge adjacent to the ATP binding site. Interaction ener-
gies of these two residues with ATP vary between activated and inhibited
complexes (Lys39: Activator JS30 -79.32 ± 0.72 kcal mol−1. Inhibitor 1F8
-14.31 ± 4.33 kcal mol−1. Glu58: Activator JS30 62.61 ± 0.8 kcal mol−1. In-
hibitor 1F8 3.62 ± 0.82 kcal mol−1). These changes in interactions appear to
shift the position of ATP in the active site. Overall interactions of ATP with
the protein were determined by summing all individual interactions and in-
dicate that activator bound PDK1 stabilises ATP, which could also promote
reactivity. For both the activated and inhibited complexes, the interactions
of ATP with the substrate peptide seem reasonably similar, however then
considering the interaction of ATP with only the threonine which the phos-
phate is transferred to, it can be seen that the inhibitor bound simulation has
repulsive interactions (2.94 ± 2.15 kcal mol−1, while all other simulations
have attractive interactions (between -16 and -40 kcal mol−1). The values
for the extended set (including sets A and B from 3.2) can be seen in table
3.8.
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To confirm that MI results were reasonable, a test dataset was constructed
consisting of three different distance measurements: Asp78 to Gln162 (A);
Asp78 to Ser160 (B); and Ile100 to Asp142 (C). Asp78 is located in the C-
terminal lobe, while Gln162 and Ser160 are part of the activation loop. There-
fore, MI should be high for the A-B pair, as both are related to the same loop
motion and so should be correlated. Distance C was computed between
two residues located on the N-terminal lobe. This distance is not related to
loop motion, it is expected to show no correlation to the other two distances
(figure 3.49). MI was computed for each distance using the simulation with
no allosteric ligand, and results can be found in table 3.9.
FIGURE 3.49: Distances computed to check MI results are rea-
sonable. Distances A and B should be correlated, while A,C
and B,C should show less correlation.
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I(A;B) I(A;C) I(B;C)
0.985 0.134 0.142
TABLE 3.9: MI computed between distances A, B and C. Dis-
tances A, B and C are highlighted in 3.49
Values for I(A; B) are high, which suggests they show correlation, while
both I(A; C) and I(B; C) have low values, suggesting no correlation.
It is important to ascertain whether a particular MI signal is true, or a
result of noise due to finite sampling. To establish this, MI was first com-
puted between two sets of data. One set was then randomised in time, and
MI computed again. This randomised MI is then subtracted from the com-
puted MI to give Icorr. This MI was calculated for the same distances shown
above, and extended to include three further simulations. The results can
be seen in table 3.10.
I(A;B)corr I(A;C)corr I(B;C)corr
APO 0.872 0.020 0.028
1F8 0.833 0.019 0.031
2A2 1.184 0.007 0.012
JS30 1.069 0.075 0.087
TABLE 3.10: MI computed between distances A, B and C using
in house script, for four systems. Values reported as MIcorr
using 200,000 snapshots and 300 bins.
This was then computed for a range of bin numbers to establish how
both the original MI, and the randomised MI, vary depending on binning.
Taking the difference of both MI (unedited data, and then with one dataset
randomised) for each number of bins used (between 1 and 1000 bins), it was
possible to determine a maximum value of MI which can be attributed to a
real signal and not a result of noise (figure 3.50). The number of bins cor-
responding to the largest difference between these two data sets was used
for all further calculations. To facilitate analysis, MI was initially computed
on a reduced trajectory composed of 1 every 5 snapshots, reducing the data
points to 40k snapshots. In this case, 60 bins were used. Results for each
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system are shown in figure 3.50 and show the MI computed between the in-
teraction energy of ATP with the protein, and the first principal component.
MI for a range of bin numbers is higher in the unedited data compared to
the randomised set in all ligand bound simulations. However, no differ-
ence in MI is seen between original and randomised with apo simulations,
implying that for this simulation no correlation can be found between ATP
interaction energy and PC1.
These plots indicated that for the dataset comprising of 40,000 snapshots,
that around 60 bins maximised the MI signal relative to noise. Therefore the
following MI results presented are for MIcorr, as defined in 2.3.3, using 60
bins for datasets composed of 40,000 snapshots, and 100 bins for datasets
composed of 100,000 snapshots.
Further data relating to testing of MI can be found in appendix A.
3.3.6.2 MI results: Original compound set
As previous analysis suggests that the hydrogen bonding with ATP may
play a role in the changes of activity, it would be useful to determine if the
motion described by PC1 is related to the stability of ATP in the active site.
MI was therefore calculated between the value of PC1, and the interaction
energy of ATP with the protein.
As distances A and B are also related to the loop motion, MI was first
computed for the three distances as defined in 3.49, to confirm that distances
A and B show different MI to PC1, than distance C. In all cases, when there
is allosteric ligand bound, MI for both distances A and B with PC1 is higher
than for distance C for PC1. In all cases for the apo simulation, MI between
any of the distances with ATP interaction energies is negligible (table 3.11).
MI was then computed between ATP interaction energy, and value of
PC1 for each system. Results can be seen in table 3.12. To facilitate analysis,
only every second snapshot was used (100k snapshots) for a 1 µs trajectory,
and is calculated using 100 bins.
112
Chapter 3. Allosteric modulation of phosphoinositide-dependent
kinase-1 (PDK1) mediated by covalently bound small molecules
FIGURE 3.50: MI computed for a range of numbers of bins, for
original data and with one set randomised in time in plot 1.
Randomised MI subtracted from original data MI to give plot
2. A: Apo. B: inhibitor 1F8. C: activator 2A2. D: activator JS30.
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I(A;ATP(Eint)) I(B;ATP(Eint)) I(C;ATP(Eint))
APO 0.003 0.002 0.001
1F8 0.172 0.094 0.035
2A2 0.462 0.387 0.011
JS30 0.125 0.099 0.038
TABLE 3.11: MI computed between PC1 and distances A, B
and C for four systems. Values reported as MIcorr.
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3.3.7 Swapped structure trajectories
In order to validate that results are not caused only as an artefact of the crys-
tal structure, two long simulations were run using crystal structures 3ORX
and 3OTU, however swapping the ligands. Modelled protein from structure
3ORX was aligned to ligand JS30, and modelled protein 3OTU was aligned
to ligand 1F8.
3.3.7.1 ATP γ-phosphate to Peptide-Thr distance
From observation of the resulting trajectories, after around 200 ns, the pep-
tide dissociates from the active site for the inhibitor bound simulation (fig-
ure 3.51A). This is in line with results obtained from the simulation run for
the inhibitor in the inhibited conformation; the peptide does not remain
close enough to the active site for a period of time which would be required
for the phosphate transfer to occur. For the activator bound simulation (fig-
ure 3.51B), there is some fluctuation of the peptide in the first 100 ns, which
from observation of the trajectory is from the Thr end of the peptide flipping
away from the ATP site, but remaining bound to the active site by the other
end of the peptide. After this, the distances remain reasonably short, and
large sections of the trajectory are stable at distances below 4 Å.
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FIGURE 3.51: Substrate peptide Thr(O) to ATP (P-γ-
phosphate) distance for swapped structure trajectories for A:
inhibitor 1F8 bound to active conformation (structure 3OTU)
and B: activator JS30 bound to inhibited conformation (struc-
ture 3ORX).
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3.3.7.2 Specific distances: ATP γ-phosphate to Tyr54
From the original set of compounds (table 3.2A), the conformation of Tyr54
varied between the activator bound and inhibitor bound structures, with the
distance between Tyr54 and ATP being larger in the inhibitor bound struc-
ture. From the swapped trajectories, it can be seen that in the case of the
inhibitor bound simulation (figure 3.52A), the distance between Tyr54 and
ATP begins at the distance of the activator bound structure, however after
around 400 ns, the conformation flips, and resembles that of the inhibited
structure. However for the simulation of the activator bound (figure 3.52B)
to the inhibited structure this flip is not seen. It may be the case that repul-
sion of Tyr54 in the inhibited structure with residues around the active site
are enough to cause this flip within the timescale of the simulation, but not
the case for the activator bound simulation. The flipped out conformation
seen in the inhibited structure is not as sterically crowded as the flipped in
inhibited conformation (as seen in figure 3.29).
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FIGURE 3.52: Tyr54(O) to ATP (P-γ-phosphate) distance for
swapped structure trajectories for A: inhibitor 1F8 bound to
active conformation (structure 3OTU) and B: activator JS30
bound to inhibited conformation (structure 3ORX).
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3.3.7.3 Comparison to PCA on original compound set
Furthermore, the activation loop conformation obtained from the PCA in
the high activating compounds is obtained by the simulation with the inhib-
ited starting structure but with JS30 bound. This is shown in figure 3.53B,
where low values of distance correspond to the activation loop close to he-
lix C, which is a conformation of PC1 which was only seen in the higher
activating compounds. For the simulation starting from the active confor-
mation with inhibitor 1F8 bound, this conformation is not seen, as shown in
figure 3.53A, where distances remain above 15 Å throughout the simulation.
FIGURE 3.53: Helix C (Pro53) to activation loop (Lys163) dis-
tance for swapped structure trajectories for A: inhibitor bound
to active conformation and B: activator bound to inhibited
conformation.
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The closing of the loop towards the helix C which is seen in the high
activating compounds, seems to also be correlated to the position of the
peptide, as the loop closes, the peptide-ATP distance is reduced. This can
be quantified by considering the MI of these 2 distances, and results can be
seen in figure 3.54.
FIGURE 3.54: MI calculated between two distances for
swapped simulations (A: inhibitor bound to act structure and
B: activator bound to inh structure). Distances A: Peptide Thr
to γ-phosphate of ATP, B: Lys39 to Glu58, C: Tyr(O) to γ-
phosphate of ATP, and D: Activation loop to helix α-C. Higher
MI is seen for I(A; D).
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3.4 Discussion
Initial analysis of PDK1 focused on particular distances which were se-
lected based on known information from the literature. This highlighted
that for inhibitor bound PDK1, the substrate Thr residue does not remain
close enough to ATP to allow for phosphate transfer, however with any of
the allosteric activators this distance was stable at shorter distances. For
the inhibitor and activator 2A2 this was validated by repeat 100 ns simula-
tions, and in all cases the substrate moves away from the active site with
ligand 1F8 bound. The other distances computed showed potential differ-
ences when considering only the original set of four simulations, however
when extended to the full set of compounds it does not seem possible to
rank compounds depending on their level of activation.
The PCA and KL divergence analysis highlight the importance of the
activation loop in the function of PDK1. The differences in the conforma-
tion of the activation loop were confirmed using both the KL divergence
of dihedral angles, and with Cα coordinate PCA, which both show differ-
ences between activated and inhibited PDK1. When extended to the full
set of compounds it was again difficult to establish a trend relating to dif-
ferent levels of activation. By then computing the interaction energies of
ATP with the protein, it suggests that there is correlation between the loop
motion and the interactions with ATP at the active site as values of MI be-
tween these two variables are higher than for simulations with no allosteric
ligand bound. Further studies to confirm this hypothesis could be done by
carrying out mutations of key residues which interact with ATP and the
activation loop; such as Lys39, Glu58, or Tyr54.
To further understand the allosteric mechanism of PDK1 activation and
inhibition, the work by Schulze et al. [88] should be investigated further. An
overall description of the allosteric mechanism of PDK1 should include both
the findings from this thesis; but also account for the changes in the global
‘hinge-twist’ motion, and the changes in the length of α-helix B, which were




Small molecule allosteric effects
on the WPD loop
of protein tyrosine phosphatase 1B
(PTP1B)
4.1 Introduction
4.1.1 Protein phosphatases as a drug target
Protein phosphatases carry out the reverse function to protein kinases, in
that they dephosphorylate their substrates by hydrolysis of a phosphoester
at Ser, Thr or Tyr residues. There are far fewer phosphatases than kinases:
200 phosphatases compared to around 518 kinases. Initially it was believed
that phosphatases were not as useful drug targets as kinases to regulate
aberrant phosphorylation controlled signalling pathways [126–128], as their
regulatory function was not clearly understood, and so were overlooked
while focus was on protein kinases. However both kinases and phosphatases
are just the "on" and "off" switches in these signalling pathways: either can
dysfunction, and either may require their activity to be modulated. Simi-
larly to kinases, dysregulation of phosphatases has been implicated in many
different disease pathways, including cancer, diabetes and obesity, and also
for immune and neurodegenerative disorders [127, 129–131].
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Phosphatases can either act on Ser/Thr, or Tyr, and some have dual
specificity. Despite there being over 400 Ser/Thr kinases, there are remark-
ably few Ser/Thr phosphatases (PSPs), only around 30. These are split
into three families: PPPs (phospho-protein phosphatases); PPMs (metal-
dependant protein phosphatases) and a class of Asp based phosphatases.
In the case of PPPs, the fact that so few phosphatases can regulate the ac-
tivity of many different substrates, has been linked to their ability to bind
many different regulatory domains, and in fact all within this class are mul-
timeric proteins. PPMs in contrast, bind either Mg2+ or Mn2+, however
they contain domains other than the catalytic domain which may facilitate
substrate selection [132, 133].
Protein tyrosine phosphatases (PTPs) account for the largest number of
protein phosphatases. There are three main classes of PTPs, which are de-
fined based on their catalytic residue. The majority (116 out of 125) have a
cysteine as the residue which receives the phosphate from the substrate, and
the remaining 9 have either aspartic acid, or histidine. Further classification
of the cysteine phosphatases is based on sequence similarity and function.
Class I includes around 95% of Cys-PTPs [128, 129, 134], and all have a con-
served active site sequence. Class I is then further split into two subgroups:
those which only dephosphorylate tyrosine, and those with dual specificity
for Ser/Thr and Tyr. The remaining two classes (II-III) include only a few
members.
Protein tyrosine phosphatases are implicated in a large range of disease
pathways [135], depending on the particular PTP. For example, many are
associated with cancer, such as CDKN3 [136], PTEN [137], DUSP16 [138] or
CD45/PTPRC [139, 140]. Others such as PTP1B [141, 142] or LMPTP [143]
are targets to treat diabetes or obesity . Neurodegenerative diseases such as
Alzheimer’s and Parkinson’s also may be linked to function of PTPs such as
STEP [144] or SYNJI [145].
Yet while there has been significant success in development of kinase
inhibitors (over 30 with FDA approval), there have been no phosphatase
inhibitors approved, and only a very small number have reached clinical
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trials. The issues are mostly with selectivity, since the active site is well con-
served across many phosphatases in both sequence and structure and many
considered PTPs to be "undruggable" [146, 147]. In addition to selectivity,
P-Tyr mimetics which bind to the active site require them to be charged
molecules, as the side chains which bind P-Tyr are positively charged. This
then also leads to issues with cell permeability [130, 148].
Many allosteric sites on PTPs are known, and often these sites are less
conserved between close family members. In addition, there is then the
opportunity to select sites which do not require such charged molecules.
4.1.2 PTP1B Protein tyrosine phosphatase 1B
PTP1B is a tyrosine phoshpatase; the initial member of the class I PTPs and
the first to be confirmed as a therapeutic target [149]. It is encoded by the
PTPN1 gene, and as it negatively regulates the insulin pathway, it has been
of interest as a target for treatment of obesity and diabetes. In studies of
PTP1B-knockout mice, this role was confirmed, and mice show resistance to
both obesity and diabetes [150]. However there is also interest in targeting
PTP1B for a range of other conditions, including liver diseases [151] and
cancer [152–154].
Initial developments of active site inhibitors yielded several compounds
which have structures based on the P-Tyr substrate of PTP1B, or those which
bind to both the active site and an adjacent binding pocket [130]. However
it still remains that the lack of selectivity by using P-Tyr mimetics is a ma-
jor challenge, and as a result, focus has shifted to allosteric sites. However
as of yet only a very small number (3-4) of PTP1B inhibitors have reached
the clinic. Those which have, were stopped in majority due to selectivity
issues, such as Ertiprotafib, which reached Phase II trials, but off target
binding resulted in toxicity issues [155]. Also Trodusquemine showed some
promise, trials were previously suspended again due to selectivity concerns.
However it is possible that research on this compound will recommence as
Novo Biosciences were awarded further funding to continue investigating
the scope for this compound [128, 155, 156].
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FIGURE 4.1: Structural features of PTP1B. Phophate is trans-
ferred from the P-Tyr substrate to Cys215 at the active site
(teal). The WPD loop must be open for the substrate to bind,
and closes over the substrate to position key residues for catal-
ysis.
The structure of PTP1B is shown in figure 4.1, highlighting the important
structural features. The active site contains an arginine residue, which facil-
itates substrate P-Tyr binding and allows for nucleophilic attack by Cys215,
illustrated in figure 4.2. In order for the substrate to access the active site,
the WPD loop moves to an open conformation, which allows the substrate
to bind, after which the loop closes (figure 4.3), and interactions of an aspar-
tic acid on the WPD loop with the substrate allow for phosphate transfer.
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FIGURE 4.2: Mechanism of dephosphorylation of substrate.
Arg221 facilitates substrate binding. Phosphate is transferred
to Cys215. Asp181 on the WPD loop provides H+ in substrate-
phosphate bond breaking.
FIGURE 4.3: Open and closed conformations of the WPD loop.
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PTP1B has two currently known allosteric sites, one which is a pocket
formed by the α-3, α-6 and α-7 helices [157]. The other site was more re-
cently discovered [158], and sits on the other side of α-3 as shown in figure
4.4. The current understanding is that binding of an inhibitor stabilises the
inactive conformation of the WPD loop (figure 4.1), however it is unclear ex-
actly how this stabilisation occurs. Some mechanistic understanding can be
obtained for specific ligands, however there currently seems to be no way
to apply this to rational design of new compounds.
FIGURE 4.4: Two known allosteric sites of PTP1B. Inhibitor
FRJ (PDB ID 1T4J) shown in purple, and inhibitor D0P shown
in blue (PDB ID 6B95). Colours of structural features of PTP1B





Simulations were set up for two different inhibitors, which are bound to two
different allosteric sites. The first is from crystal structure PDB ID 1T4J and
the second from PDB ID 6B95 (figure 4.4).
For 1T4J, partial charges were derived using the AM1-BCC methodology
using Antechamber [98]. For 6B95, the ligand is covalently bound to the al-
losteric site, and methods described in section 3.2.1.1 were used to describe
the ligand-cysteine bond.
4.2.1.2 Protein preparation
Crystal structures were found in the PDB database, PDB ID 1SUG (closed
WPD loop), 2HNP (open WPD loop), 1T4J (open loop with inhibitor FRJ)
and 6B95 (open loop with inhibitor D0P). The sequence used for all mod-
els includes residues Met1 to Leu299. All His were modelled as HIE except
His214 which is modelled as HID, as this residue forms an H bond network
with Tyr124 and His173. For structure 1SUG, only residue Met1 was miss-
ing. For structure 2HNP, α helix 7 was missing (residues 283-298) and so co-
ordinates for these residues were taken from 1SUG. This was validated by
modelling these using the multi-structure alignment of MODELLER [100]
and the helix is an identical position. For structure 1T4J, residues 284-289
were missing, and were modelled using MODELLER. As residues 290-298
are present in the crystal structure, it is clear that with inhibitor bound, α
helix 7 is disordered, as the ordered helix of 1SUG would conflict with the
binding site of the allosteric inhibitor. For structure 6B95, residues 279-299
were modelled using MODELLER. This structure has three mutations rela-
tive to the other structures of PTP1B. One of these is necessary to retain, as
it is the Cys residue which the allosteric ligand is covalently bound to. The
other two mutations have been altered in order to compare directly with the
other simulations. In all cases, crystal waters and ions were removed, and
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the protein structure was prepared using Maestro [101]: missing hydrogen
atoms were added, and N-methyl and acetyl groups were added to the C
and N terminal ends of the protein respectively.
4.2.1.3 Substrate peptide
Three peptide substrate complexes have been found for PTP1B, and have
available crystal structures (1EEN, 1EEO, 4ZRT). The peptide with sequence
ACE-ELEF-(Y-phos)-MDYE-NH2 was selected for simulations, using coor-
dinates for the peptide from crystal structure PDB ID 1EEO. In all cases, the
substrate to active site distance was kept reasonably constant at the start of
the simulation (between 2.2 - 2.8 Å).
4.2.1.4 Ligand substrate protein complexes
In each case, a complex was set up including protein along with the sub-
strate peptide or substrate peptide with allosteric ligand using the software
leap from the Amber16 software package [159]. General Amber Force Field
parameters were assigned to ligand atoms with the addition of the adapted
disulphide bond parameters discussed previously, while the FF14SB-ILDN
force field [45] was used to describe the protein. Phosphate parameters de-
veloped by Case et al. [112] were used to describe the phosphotyrosine
located on the substrate peptide. Each model complex was then solvated in
a box of TIP3P water molecules extending 10 Å from the edge of the solute,
and Na+ ions added to neutralise the net charge of the complex.
General Amber Force Field parameters were assigned to ligand atoms
with the addition of the adapted disulphide bond parameters (as per method
described in section 3.2.1.1) for the simulation based on structure PDBID
6B95, while the FF14SB-ILDN force field [45] was used to describe the pro-
tein. Phosphate parameters developed by Case et al. [112] were used to
describe the phosphotyrosine of the substrate peptide.
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4.2.2 Molecular dynamics simulations
4.2.2.1 Equilibrium MD simulations
The resulting solvated models were energy minimised with sander, and
equilibrated at NVT using PMEMD (CUDA), from the software package
Amber16 [159]. Energy minimisation using 200 steps of conjugate gradient
with restraints on the solute was carried out in order to equilibrate only the
solvent. This was then followed by 5500 steps of conjugate gradient fol-
lowed by 1500 steps of steepest descent, with restraints only on the WPD
loop and the substrate. The system was then heated to 298 K in four steps
using the Berendsen thermostat [52], each of 100 ps, with harmonic Carte-
sian positional restraints of 10 kcal mol−1 Å−1 on the substrate and on the
WPD loop. A further 5 ns was run in the NPT ensemble while retaining the
restraints, in order to equilibrate the density of the system. The restraints
were then removed over a further 800 ps at NVT. A further 5 ns in the NPT
enemble was run prior to the production run. Equilibrium molecular dy-
namics simulations were run using PMEMD (CUDA), for a simulation time
of 1 µs using a 2 fs timestep. Throughout all equilibration and production
MD, SHAKE was applied to constrain all bonds involving hydrogen. PME
was used to describe the long range electrostatic interactions using a cutoff
of 8 Å. In all simulations, snapshots were saved every 5 ps, resulting in 200k
snapshots for every 1 µs simulation.
Simulations were started from both open and closed WPD loop in each
case. Systems set up were: substrate only, substrate with inhibitor FRJ (1T4J)
and substrate with inhibitor D0P (6B95). Simulations without substrate or
allosteric ligand were also run for comparison.
4.2.2.2 Steered MD simulations
In order to obtain intermediate conformations between the open and closed
WPD loop states, steered MD (sMD) was performed using Gromacs [160]
with Plumed [161]. Starting structures for the substrate bound open and
closed conformations were taken from the PDB, using structures PDB ID
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2HNP for the open conformation and PDB ID 1SUG for the closed confor-
mation. The conformation of Trp179 was altered in structure 2HNP (see
section 4.3.1) by adjusting both chi1 and chi2 torsional angles. The substrate
used was the same as described in section 4.2.1.3.
4.2.2.3 Seeded equilibrium MD simulations
Coordinates were extracted from the steered MD simulations as starting
points for many short equilibrium MD simulations. RMSD of the WPD loop
was monitored for the sMD simulation and 200 structures representing a
range of values of RMSD were selected. For each structure, minimisation,
equilibration and production MD simulations were run using the same con-
ditions detailed in section 4.2.2.1.
4.2.3 MSM generation
A Markov State Model (MSM) was constructed using both the equilibrium
MD simulations and seeded simulations from the steered MD, using the
pyEMMA software package (version 2.5.4) [116]. In order to reduce the
dimensionality of the dataset and define separate states, descriptors were
selected which highlight differences between the active and inactive con-
formations. The RMSD of the WPD loop (residues 180-185 were included)
relative to the their position on the open WPD loop structure, and the sub-
strate to Cys215 distance were selected as input dimensions. K-means clus-
tering using 100 clusters was used to define a set of microstates. In order to
obtain a separation of timescales for both the substrate and substrate plus
inhibitor data sets, initial clustering was completed separately on each set
of data. A range of implied timescales were computed using lag times be-
tween 1 and 10000 steps. A lag time of 3000 steps (30 ns) was selected for
the initial model, based on plots generated for a range of implicit timescales,
as shown in figure 4.22. Three macrostates were then selected to define the
slow processes. The k-means clusters were separated into three groups with
a hidden Bayesian Markov Model [162].
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A second model was constructed, again using a k-means clustering of
100 clusters, however clustering was performed on the combined set of sim-
ulations including the substrate only simulations, and the substrate with in-
hibitor simulations. A lag time of 2000 steps (20 ns) was selected. For this
model, assignment of the 100 microstates into three macrostates was done
using PCCA [163, 164].
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4.3 Results
4.3.1 Protein structures
Initial models based on the structure of PDB ID 2HNP highlighted potential
inaccuracies with the conformation of the side chain of Trp179 when carry-
ing out the loop closure using sMD. By applying only a bias of the WPD
loop RMSD to the closed conformation, it was not possible to close the loop.
This was due to the conformation of Trp179 which must be flipped before
the loop closed, as it is flipped in the closed structure, and obstructs the loop
closure (figure 4.5). If the loop is even partially closed, there is insufficient
space for this flip to occur. Further attempts at sMD included bias based on
both the loop RMSD and the chi1 and chi2 torsions of Trp179 residue, and
as long as the Trp had flipped conformation before closing the loop, this was
possible. RMSD plots of this process are shown in section 4.3.2.
However in more recently released inhibitor bound crystal structures
(6B95 and related structures), it was apparent that none had the initial Trp
conformation of 2HNP. A further search of the PDB found no other PTP1B
structures with the same conformation of this side chain. On checking the
electron density of 2HNP it became apparent that this Trp conformation was
not visible at all in the electron density. It seems likely that this is an error,
since other structures which show better resolution have the flipped confor-
mation. Therefore further sMD was carried out with the Trp in the flipped
conformation shown in dark grey in figure 4.5, by manual adjustment of the
model constructed from 2HNP, and only loop RMSD used as a bias for the
steered MD. Several previous equilibrium MD and steered MD use 2HNP
as a starting point, and as this conformation of Trp affects the loop closure,
this could affect the outcome [165–168].
4.3.2 Steered MD simulations
With the unaltered structure of PDB ID 2HNP, initial attempts at steered
MD to close the WPD loop resulted in reaching only a minimum RMSD of
around 2 Å, or with an increased force constant caused the protein to unfold.
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FIGURE 4.5: Conformation of Trp179 in PDB ID 2HNP (teal),
and the proposed corrected conformation (grey).
Plots showing RMSD of the WPD loop over time can be seen in figure 4.6
for these attempts.
As was discussed above, the issue with the loop closure is the initial con-
formation of Trp179 in PDB ID 2HNP, which must flip prior to loop closing.
As this caused problems when using the RMSD of the loop alone, additional
steps were added to the steered MD to bias the motion of the χ1 and χ2 tor-
sions of Trp179. Provided the flip occurred in the initial stages of WPD loop
closure, it was possible to reach RMSD 1 Å over a 150 ns sMD simulation.
However this later proved to be unnecessary, as it is very likely that the Trp
conformation obtained from crystal structure 2HNP is incorrect. Bias using
RMSD alone was then possible, to reach a final RMSD of around 1 Å.
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FIGURE 4.6: Steered MD simulations. A: unaltered structure
of 2HNP using a force constant of 2500 kJ mol−1. B: unaltered
structure of 2HNP using a force constant of 3500 kJ mol−1. C:
altered Trp179 conformation of 2HNP structure using a force
constant of 2500 kJ mol−1.
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4.3.3 Loop conformation
Long MD of four complexes were initially analysed. Codes in brackets
shown below are used to refer to each of these simulations in the follow-
ing discussion.
• Substrate bound: open WPD loop (SO).
• Substrate bound: closed WPD loop (SC).
• Substrate and inhibitor FRJ bound: open WPD loop (IO).
• Substrate and inhibitor FRJ bound bound: closed WPD loop (IC).
Of these four simulations from observation of the trajectory, only one
visited conformations of the WPD loop which vary from its start point (i.e.
open to closed, or closed to open). In the IC simulation, the loop opens at
around 500-520 ns, as in figure 4.7, and remains open for the next 500ns.
FIGURE 4.7: Snapshots of all four systems at 500 ns and 520
ns. Teal: SO. Red: SC. Purple: IO. Green: IC.
Plots showing the RMSD per snapshot, and distributions of RMSD for
each simulation were then plotted, to highlight differences in behaviour.
In figure 4.8, comparison of the SO and the IO simulations show only a
small shift in the distribution of values, and both show a reasonably large
range of values suggesting the loop is reasonably flexible in both cases. The
SC simulation shows a much more narrow range of values, and the loop is
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FIGURE 4.8: RMSD of residues Pro181-Pro186 relative to the
closed loop conformation. Teal: SO. Red: SC. Purple: IO.
Green: IC.
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much more stable in the closed conformation, which can be seen from the
time plot. However it can be seen in the time plot for the IC simulation, that
at around 500 ns the RMSD relative to closed starts to change.
This is mirrored in the same plots, but with RMSD calculated relative to
the open conformation, as seen in figure 4.9. This suggests that the differ-
ence in activity is due to the destabilisation of the closed state when inhibitor
is bound. In both cases, the distributions of the open state seem unaffected
by whether there is inhibitor bound or not.
For each set of RMSDs computed (relative to closed or open), the JS
divergence was calculated for each pair of simulations, and results are in
figure 4.10. This confirms that relative to the closed conformation, the SC
simulation has a larger JS divergence to both closed conformations than the
IC simulation. It also confirms that both the substrate and inhibitor bound
open conformations are similar, as JS divergence values are very small. The
same can be seen in the plot relative to the open conformation, and the JS
divergence values of the inhibitor closed state take values between the max-
imum and minimum JS for any pair. This is because the inhibitor closed
simulation has part of the distribution in the open state, and part in the
closed state. Distributions of RMSD for residues Thr177-Glu186 were also
computed and can be found in appendix C.
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FIGURE 4.9: RMSD of residues Pro181-Pro186 relative to the
open loop conformation. Teal: SO. Red: SC. Purple: IO. Green:
IC.
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FIGURE 4.10: JS divergence of distributions of RMSD com-
puted relative to A: closed and B: open. Clustering described
in section 3.2.8, using ε=0.15 with 2 states.
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4.3.3.1 Extending analysis to include inhibitor D0P
Further simulations were completed for allosteric inhibitor D0P, which binds
to an alternate allosteric site to ligand FRJ. The RMSD analysis completed
above was then repeated for these simulations. Simulations with both sub-
strate and ligand D0P were started from both the closed and open WPD
loop conformations, and RMSD relative to the closed and open conforma-
tions were computed.
As with ligand FRJ, the closed conformation with ligand D0P was not
stable, and within around 100 ns the loop opens for this simulation. Figures
4.11 and 4.12 show distributions and time series for the simuations with
ligand D0P bound. RMSD is computed for residues Pro181-Pro186. Distri-
butions of the substrate open (SO) and substrate closed (SC) RMSD are also
shown as a reference.
4.3. Results 143
FIGURE 4.11: RMSD of residues Pro181-Pro186 relative to the
closed loop conformation. Teal: SO. Red: SC. Magenta: D0P
open. Blue: D0P closed.
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FIGURE 4.12: RMSD of residues Pro181-Pro186 relative to the
open loop conformation. Teal: SO. Red: SC. Magenta: D0P
open. Blue: D0P closed.
4.3. Results 145
4.3.4 Equilibrium MD KL analysis
Equilibrium MD simulations for the SO, IO, SC and IC simulations were
compared using KL divergence of torsional angles. Comparison of the SO
and IO simulations shows that the largest differences in backbone torsions
are around the active site, as shown in figure 4.13B1 and B2. The KL values
for the sidechain torsions highlighted four residues located around the al-
losteric site and near to the WPD loop, namely Tyr153, Try154, Asn194 and
Glu277. The difference in Glu277 is understandable, as this sits directly in
the allosteric site.
For the comparison of the SC and IC simulations, the result is less clear,
and residues with the largest backbone and sidechain KL values are located
away from both the active and allosteric sites.
This emphasises the need for a multi-approach analysis, as while KL of
torsional angles can give useful insights in some cases, it may not always be
the case that large enough differences are seen.
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FIGURE 4.13: KL divergence computed for the open and
closed conformation simulations. Figures show KL results
for A1: KLbackbone(SC||IC). A2: KLsidechain(SC||IC). B1:
KLbackbone(SO||IO). B2: KLsidechain(SO||IO).
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4.3.5 Distributions of distances relating to reaction mecha-
nism
Several distances were calculated based on known information about the
mechanism. As highlighted in figure 4.2, the substrate P-Tyr must remain
at a distance to Cys215 to allow phosphate transfer to occur. Furthermore,
Asp181 on the WPD loop should interact with the substrate, as deprotona-
tion of this residue is required during the breaking of the substrate-phosphate
bond. Distributions of these distances were therefore calculated for each
system to allow differences between substrate and inhibitor bound simula-
tions to be assessed.
FIGURE 4.14: Three distances computed for each system.
Asp181(C) to P-Tyr(O); Cys215(S) to P-Tyr(P); Ile219(N) to P-
Tyr(P).
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FIGURE 4.15: Distance from Cys215 to substrate P-Tyr. Teal:
SO. Red: SC. Purple: IO. Green: IC.
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The substrate remains at reasonably short distances (< 5 Å) in the SO,
and SC simulations, with values for the SC simulation remaining in a nar-
row distribution between 3 and 4 Å. In the SO simulation, the distribution
is broader, and maximum values increase to around 6 Å. With inhibitor
bound, the closed conformation shows two peaks in the distribution of val-
ues, which correspond to the two segments of the trajectory: up to 500 ns
before the loop opens, and after the loop begins to open. This can be seen
from the time plot in figure 4.15, where at around 500 ns the value increases.
With the IO simulation, the substrate only remains close to the active site
for around 30 ns. After this time, the substrate remains bound to PTP1B,
but moves noticeably away from the active site. The comparison of the SO
and the IO highlights a potential destabilisation of binding of the substrate,
when allosteric ligand is bound. The distance of Asp181 to the active site
was measured as Asp181 is involved in the reaction mechanism, as detailed
in figure 4.2. From the distributions shown in figure 4.16, it can be seen
that the open conformation for the substrate and inhibitor vary, however
the closed conformation shows a larger difference due to the loop opening
in the IC simulation. The Ile219 to substrate distance (figure 4.17) shows a
similar pattern to the Cys215 to substrate distance, as they both relate to how
close the substrate P-Tyr is to the active site. However in this case, the dis-
tribution of the IC simulation is at shorter distances than the SC simulation,
in contrast to the Cys215 distance. This could result in different positioning
of the substrate in the active site, and not allow the shorter Cys215-P-Tyr
distances required for catalysis to occur.
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FIGURE 4.16: Distance from Asp181 to substrate P-Tyr. Teal:
SO. Red: SC. Purple: IO. Green: IC.
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FIGURE 4.17: Distance from Ile219 to substrate P-Tyr. Teal:
SO. Red: SC. Purple: IO. Green: IC.
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4.3.6 PCA on Cα coordinates
The first and second eigenvectors correspond to 17.88% and 15.67% of the
variance respectively. The sum of the first 10 eigenvectors accounts for
60.85% of the variance. The first principal component relates to both the
WPD loop (residues Pro180-Val184) and the R-loop (residues Met114-Lys120)
with a higher contribution to the variance from the R-loop. A per atom con-
tribution to PC1 is shown in figure 4.18, along with distributions of PC1 for
each system, and structures corresponding to the maximum and minimum
values of PC1.
PC2 also relates to another motion of the WPD loop, and per atom con-
tributions, distributions of PC2, and minimum and maximum structures are
shown in figure 4.19. Plotting PC1 and PC2 as a 2D histogram, two states
can be seen (figure 4.20(A)), one representing the open loop and the other
the closed loop. Each of the four trajectory can then be plotted on this pro-
jection (figure 4.20(B)), which highlights that only the inhibitor bound sim-
ulation (green) which begins from the closed conformation, moves to the
other, open state. This confirms the analysis discussed in 4.3.3.
For both PC1 and PC2, the JS divergence was computed in order to com-
pare the distributions for each system. PC1 has higher JS divergence be-
tween the open and closed simulations, with maximum values of over 0.6.
Substrate and inhibitor simulations starting from the closed conformation
are similar, as are those starting from the open conformation, which can be
seen with JS values of around 0.15 or less for both. PC2 results show the
differences which were discussed previously. The substrate and inhibitor
simulations beginning from the closed conformation show around the same
JS divergence as the inhibitor closed to the substrate open. The largest JS
divergence of PC2 is between the substrate open and substrate closed sim-
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FIGURE 4.20: A: Distributions of PC1 plotted vs PC2, with in-
creasing probability coloured blue-green-yellow-red. B: Same
projection of PC1 vs PC2 with each trajectory superimposed.
Teal: SO. Red: SC. Purple: IO. Green: IC.
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FIGURE 4.21: JS divergence for A: PC1, and B: PC2 for four




As we have information for this system on both the active and inactive con-
formations, it would be useful to better understand the mechanism which
causes the inhibitor to destabilise the closed conformation. The previous
analysis gives some insights to the loop opening when inhibitor is bound,
however we have not been able to sample the loop closing using equilib-
rium MD simulations. Furthermore, it is important to understand in more
detail the mechanism which the inhibitor causes the loop to open and to
confirm that this occurs in a statistically significant way.
To determine a possible pathway and intermediate states, an MSM was
constructed, which uses four equilibrium MD simulations (substrate with
open WPD loops; substrate with closed WPD loop; substrate and inhibitor
with open WPD loop; substrate and inhibitor with closed WPD loop), and
the equilibrium MD runs which were seeded from the steered MD for each
system, as described in section 4.2.2.2.
The initial model constructed uses separate clustering for the substrate
bound set, and the substrate with inhibitor bound set. This resulted in rea-
sonably similar clustering however direct comparison is not possible. The
second model allowed for clustering to be done on the entire dataset. In
both cases, the "active" conformation has been defined as the closed WPD
loop (using the RMSD of both backbone and sidechain atoms) with the sub-
strate at shorter distances to the active site cysteine residue. The "inactive"
conformation is defined as the open WPD loop with the substrate at longer
distances.
4.3.7.1 Initial MSM model
A range of implied timescales were computed and the results can be seen in
figure 4.22 for each system. From the implied timescales, a lagtime of 3000
steps (30 ns) was selected to construct the MSM.
Plots highlighting the structure of a three macrostate model are shown
in figure 4.23 for both the substrate only, and the substrate with inhibitor
(FRJ) simulations. Clustering in this case is done separately for each set of
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FIGURE 4.22: Implied timescale for substrate and inhibitor
simulations based on each set clustered separately, with 100
clusters.
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trajectories. As a result, timescales and populations of each state cannot be
directly compared, however as the input dimensions are easy to interpret,
comparison of the relative populations and relative timescales are still valid.
This shows that the most active state (orange) is much more likely with no
inhibitor bound (9.83 %), than with inhibitor bound (0.63 %). Also when
inhibitor is bound almost 90 % is assigned to the most inactive state (ma-
genta). This can be explained by considering the rates of transition between
each state. These are computed as the mean first passage time (MFPTs) be-
tween macrostates which are calculated as a weighted average of MFPTs
between each pair of microstates. Uncertainties are estimated as standard
deviations of the mean. This shows that both the magenta and teal states
have longer relative timescales (i.e. the ratio of the transition timescales in
and out of a state) to transition to the active state (orange) when inhibitor is
bound.
In both cases, three states are defined by the different coloured cluster
centres: magenta (open WPD loop with substrate at longer distances to ac-
tive site); teal (open WPD loop with substrate at shorter distances to active
site); and orange (closed WPD loop with substrate at shorter distances to ac-
tive site). With no inhibitor bound, the clusters for the magenta state reach a
maximum substrate distance of around 8 Å. However in the inhibitor bound
simulations, the maximum distance is much larger. This can be seen in more
detail in figure 4.24, where structures for each state shown in colour repre-
sent the average structure for each macrostate, based on selection of 1000
structures from each state. With only substrate bound, the average structure
in the magenta state has a substrate to active site distance of 4.1 Å however
when inhibitor is also bound the average structure has an average substrate
distance of 6.7 Å.
The selection of three macrostates to construct the MSM was validated
by carrying out Chapman-Kolmogorow (CK) test, to confirm that the the
Markov property holds. The results of this test are seen in figures 4.25 for
the substrate only set, and 4.26 for the inhibitor bound set.
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FIGURE 4.23: Clustering using 100 k-means clusters for each
set done separately, with A: Substrate only set and B: Substrate
with inhibitor FRJ set. Colours of clustercenters correspond to
macrostate assigned to.
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FIGURE 4.24: Three macrostates defined based on colouring
from figure 4.23. A: Substrate bound simulations. B: inhibitor
bound simulations. Transition timescales are in units of µs.
Distances noted are the average distance of active site Cys(S)
to substrate P-Tyr(P) for each state.
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FIGURE 4.25: Chapman-Kolmogorow (CK) test for substrate
model with separate clustering.
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FIGURE 4.26: Chapman-Kolmogorow (CK) test for inhibitor
model with separate clustering.
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4.3.7.2 Improved MSM model
A second MSM was generated in order to attempt to cluster the entire dataset
and project both the substrate, and the inhibitor bound simulation sets onto
the same cluster centres. In figure 4.27, the implied timescales for a range
of lag time τ are shown. Considering the result for both the substrate and
inhibitor plots, a lag time of 2000 steps (20 ns) was selected to build the
MSM. In the implied timescale plot for the substrate set, it is possible to re-
solve three separate processes, whereas in the inhibitor set this is likely only
two. Timescales are similar but slightly slower in the substrate data set (con-
verging between 103 to 104 steps) compared to the inhibitor set (converging
around 103).
In this instance, instead of using the hidden markov model to obtain
macrostates, PCCA was used. This allowed for three macrostates to be de-
fined for each system, which correspond to the most active state (orange:
WPD loop closed, substrate at short distances), an intermediate state (teal:
WPD loop open or closed, substrate at short-medium distances), and the
inactive conformation (magenta: WPD loop open, substrate at longer dis-
tances). This now allows direct comparison of the substrate, and substrate
with inhibitor simulations.
A coarse grain description of the microstates shows variation in the in-
termediate (teal) state when comparing both the substrate and inhibitor sets
(figure 4.28). For the substrate bound simulations only 18 of the 100 clusters
are assigned to the intermediate (teal) state. In contrast, the inhibitor bound
simulation set assigns far more clusters to this state.
In figure 4.29 the conformations for each state are highlighted. Structures
for each state represent the average structure for each macrostate, based on
selection of 100k structures from each state. For the inhibitor bound simu-
lations, over 95 % of structures as assigned to the inactive (magenta) con-
formation. While for the substrate set this is only around 5 %. The confor-
mation of the intermediate (teal) conformation varies between each system.
As the structures used to illustrate this model are averages of structures as-
signed to each state, these vary due to the assignment of clusters shown
in figure 4.28. The substrate set has far more clusters assigned to the teal
4.3. Results 165
macrostate, and as such the average structures are obtained from a different
number of cluster centers.
It can be seen from the transition rates between states shown in figure
4.29, that the transitions into the active (orange) state from both the inac-
tive (magenta) and intermediate (teal) states are slower when in inhibitor
is bound, by around a factor of 8. In addition, the timescale to move from
the active to inactive states directly is faster when inhibitor is bound. As
was discussed in section 4.3.5 and in figure 4.15, the substrate remains at
reasonably close distances to the active site even with the open WPD loop
conformation, only when no inhibitor is bound. This then allows for the
higher population of the intermediate (teal) state for the substrate simula-
tion set.
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FIGURE 4.27: Implied timescale for A: substrate and B: in-
hibitor simulations based on combined clustering, with 100
clusters.
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FIGURE 4.28: Clustering using 100 k-means clusters, with
A: Substrate only set and B: Substrate with inhibitor FRJ set.
Colours of clustercenters correspond to macrostate assigned
to.
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FIGURE 4.29: Three macrostates defined based on colouring
from figure 4.28. A: Substrate bound simulations. B: inhibitor
bound simulations. Transition timescales are in units of µs.
Distances noted are the average distance of active site Cys(S)
to substrate P-Tyr(P) for each state.
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FIGURE 4.30: Chapman-Kolmogorow (CK) test for substrate
model with combined clustering.
Again the Chapman-Kolmogorow (CK) test was used to determine if
the three state model was suitable and results are shown in figures 4.30 and
4.31. In both this model and the previous model, the CK test confirms that
the processes obey Markovianity.
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FIGURE 4.31: Chapman-Kolmogorow (CK) test for inhibitor
model with combined clustering.
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4.4 Discussion
Equilibrium MD simulations of PTP1B starting from both the open and
closed WPD loop conformations, with and without allosteric inhibitor, have
given some insights in the motions of the WPD loop. In each of the sim-
ulations with two different allosteric inhibitors (FRJ and D0P), the closed
conformation was not stable, and the loop opens on a timescale of a few
hundred nanoseconds. Starting from the open conformation, loop closing
was not observed in any of the simulations, which was expected as it is
believed that this transition occurs on the order of µs to ms. Analysis of
RMSD values higlighted that the open conformation does not seem to vary
between the inhibitor bound and inhibitor free simulations.
The two MSM models constructed both qualitatively show the same re-
sult: that the inhibitor bound set has the highest probability of occupying
the inactive (open WPD loop; long substrate distance) state. Comparison of
both models by comparing the ITs and the CK test plots does not suggest
that one model is better than the other, however as the clustering was done
for the second model using the entire data set, then the resulting popula-
toins of states, and transition timescales for both the substrate and inhibitor
systems can be compared directly. In both models, transitions into the most
active state (closed WPD loop; short substrate distance) when inhibitor is
bound are much slower than when no inhibitor is bound, and populations






In this thesis, molecular dynamics simulations combined with an informa-
tion theory based analysis have provided key insights into the mechanism
of allosteric regulation of PDK1 and PTP1B. The results highlighted the need
for tailored analysis methods, on which different metrics are required to
capture the differences between activated and inhibited conformations.
In the case of PDK1, movements of the activation loop were highlighted
using both the KL divergence of dihedral angles, and with Cα coordinate
PCA. The KL analysis showed largest variations were in residues at the
hinge region of the activation loop, while PCA confirmed this motion to
show the largest variance in atomic positions. Furthermore, the PCA analy-
sis allowed to identify distinct conformations of the activation loop between
the complexes of activator and inhibitor molecules. Specifically, in the com-
plex with inhibitor bound, it was found that the loop cannot adopt a confor-
mation that allows the substrate to be positioned within a reactive distance
to ATP. Calculating the JS divergence with application of spectral clustering
allowed for large sets of compounds to be compared easily, using differ-
ent metrics such as PCA, or distances. In addition, MI allowed to correlate
the activation loop motion with the interaction energy of ATP. The MI val-
ues obtained are relatively small, however allostery may only be a result of
very subtle changes between activated and inhibited conformations. As the
results are adjusted for noise, these values are still sufficient to confirm cor-
relation between the ATP interactions and the loop motion. Hence the com-
putational framework developed allowed to provide previously unknown
structural rational for the allosteric effects triggered by small molecules in
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PDK1. Attempts to rank compounds according to level of activity proved
to be more difficult, as while differences were still seen for most descriptors
when comparing activations to the inhibitor bound simulation, the degree
of activation did not seem to show any trend in the descriptors caculated.
For PTP1B, based on the available literature on the regulatory role of the
WPD loop, enhanced sampling methods were used to capture the loop clos-
ing process. These simulations shed light into the molecular determinants
underpinning the regulation process, challenging the previous hypothesis
of side chains causing mechanical hindrance to the movement of the loop.
In contrast, results provide a thermodynamical picture that suggest that al-
losteric inhibitors destabilise the catalytically active comformation of the
WPD loop with respect to inhibitor free complexes, but closing of the loop is
still possible in inhibitor bound complexes. This can be seen from the MSM
results, as there is still some population in the active (closed WPD loop) con-
formation, however the population of this state is low for inhibitor bound
PTP1B when compared to the population when only substrate is bound.
Equilibrium MD analysis for PTP1B found that the two different allosteric
inhibitors caused the loop to open within a few hundred nanoseconds when
simulations were started from the closed WPD loop conformation. Sim-
ulations which were started from the open WPD loop conformation did
not show significant differences in the RMSD of the WPD loop between
inhibitor bound, and inhibitor free simulations. Calculation of distances
showed that only the inhibitor bound, the open WPD loop simulation al-
lowed the substrate P-Tyr to move further away from the active site. For the
substrate bound, open loop simulation, the substrate P-Tyr still remains rea-
sonably close to the active site. This suggests that perhaps the difference in
stabilisation of the substrate with or without inhibitor is a factor, before the
loop can close. PCA of set of four simulations with inhibitor FRJ and with-
out inhibitor highlight the differences in conformation of the WPD loop, and
also the R-loop. In the closed WPD loop conformation, the variance in this
loop motion is much larger, than when the WPD loop is open.
Future work on this project should aim to extend the MI analysis with
energy decomposition. This will lead to a better understanding of specific
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interactions that allosteric ligands established and that that lead to struc-
tural differences in distant sites to the ligand binding pocket. Prediction of
these patterns will aid on the design design of new allosteric drug candi-
dates. Furthermore, combining interaction energy MI with the MSM analy-






A.1 Specific distance figures
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FIGURE A.1: Distance per snapshot of substrate peptide Thr to
γ-phosphate of ATP distance for the four original simulations
completed.
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FIGURE A.2: Distance per snapshot of Lys39 to Glu58 distance
for the four original simulations completed.
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FIGURE A.3: Distance per snapshot of Tyr54 to Glu58 distance
to γ-phosphate of ATP for the four original simulations com-
pleted.
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FIGURE A.4: Distance per snapshot of Tyr54 to phosphoserine
distance to γ-phosphate of ATP for the four original simula-
tions completed.
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FIGURE A.5: PC1 value per snapshot for the four original sim-
ulations completed.
A.2 PCA figures
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FIGURE A.6: PC1 vs PC2 2D distribution, with individual tra-
jectories superimposed showing 1 every 300 snapshots.
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A.3 MI testing
APO MI MI(rand) MI(corr)
AB 0.985 0.112 0.872
AC 0.134 0.114 0.020
BC 0.142 0.114 0.028
1F8 MI MI(rand) MI(corr)
AB 0.966 0.134 0.833
AC 0.139 0.120 0.019
BC 0.150 0.120 0.031
2A2 MI MI(rand) MI(corr)
AB 1.372 0.187 1.184
AC 0.138 0.131 0.007
BC 0.145 0.133 0.012
JS30 MI MI(rand) MI(corr)
AB 1.243 0.175 1.069
AC 0.228 0.153 0.075
BC 0.233 0.146 0.087
TABLE A.1: Full testing values for MI computed between dis-
tances A, B and C using 200,000 snapshots and 300 bins.
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APO MI MI(rand) MI(corr)
A 0.033 0.030 0.003
B 0.031 0.029 0.002
C 0.031 0.030 0.001
ORX MI MI(rand) MI(corr)
A 0.207 0.035 0.172
B 0.129 0.036 0.094
C 0.070 0.035 0.035
ORZ MI MI(rand) MI(corr)
A 0.498 0.035 0.463
B 0.423 0.036 0.387
C 0.047 0.036 0.011
OTU MI MI(rand) MI(corr)
A 0.161 0.036 -0.016
B 0.136 0.037 -0.009
C 0.073 0.035 -0.035
TABLE A.2: Full testing values for MI computed between ATP
interaction energy, and distances A, B or C using 40,000 snap-
shots and 60 bins.
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APO MI MI(rand) MI(corr)
A 0.340 0.031 0.310
B 0.449 0.030 0.419
C 0.059 0.029 0.030
ORX MI MI(rand) MI(corr)
A 0.488 0.033 0.455
B 0.493 0.032 0.461
C 0.050 0.032 0.018
ORZ MI MI(rand) MI(corr)
A 1.067 0.040 1.027
B 1.204 0.041 1.164
C 0.042 0.033 0.008
OTU MI MI(rand) MI(corr)
A 1.290 0.037 1.253
B 1.123 0.040 1.083
C 0.155 0.036 0.119
TABLE A.3: Full testing values for MI computed between PC1,




A brief summary of the scripts available on GitHub to carry out the PCA,
KL and MI analysis is provided below. A Jupyter notebook tutorial can be
found in the GitHub repository [121].
The tutorials include an overview of the theory, method, and explain
how to format input trajectories and directory format, prior to running the
scripts. Short trajectories of PDK1 are provided in order to run the note-
books directly. Further scripts to run the analysis from the command line
are also provided.
The first notebook shown in figure B.1 details the KL divergence of tor-
sional angles. This includes details on how KL is calculated, and explains
the overall workflow as shown in figure 3.13. It is then possible to launch
a Pymol session with a script provided, which will assign KL values to the
B-factor column of the PDB file, and then visualise these as a colour scale
on the structure in Pymol. The Pymol session will include six structures.
’KL_backbone’: summed ψ and φ; ’KL_sidechain’: summed χ1 and χ2; and
then each ψ, φ, χ1 and χ2 shown separately.
The notebook to run the PCA analysis shown in B.2 again details some
background on PCA, and information on the output of the analysis. The
PCA analysis is run, and the resulting output can be loaded into pymol to
visualise both the per atom contribution to the first and second principal
component, and the structures representing the minimum and maximum
values of PC1 and PC2 for the input trajectories.
188 Appendix B. PDK1 analysis scripts
FIGURE B.1: Section of the tutorial to run KL divergence of
torsional angles available on GitHub [121].
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FIGURE B.2: Section of the tutorial to run PCA analysis avail-




Protein tyrosine phosphatase 1B:
PTP1B
C.1 Loop RMSD figures using larger number of
residues.
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FIGURE C.1: RMSD for residues Thr177-Glu186 relative to
open loop. Teal: substrate open. Red: substrate closed. Pur-
ple: inhibitor open. Green: inhibitor closed.
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FIGURE C.2: RMSD for residues Thr177-Glu186 relative to
closed loop. Teal: substrate open. Red: substrate closed. Pur-
ple: inhibitor open. Green: inhibitor closed.
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C.2 PCA
Plots showing value of PC1 and PC2 per snapshot for four simulations.
FIGURE C.3: PC1 value per snapshot for A: substrate open; B:
substrate closed; C: inhibitor open; and D: inhibitor closed.
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FIGURE C.4: PC2 value per snapshot for A: substrate open; B:





D.1 Oral and Poster presentations
D.1.1 Oral presentations
• CCP5 Summer School (Lancaster University, July 2016)
• Joseph Black conference (The University of Edinburgh, 2018)
• Astbury Conversation (Flash presentation: University of Leeds, 2018)
• MGMS Young Modellers’ Forum (University of Greenwich, 2018)
D.1.2 Poster presentations
• ScotChem conference (The University of Edinburgh 2016 & University
of Glasgow 2017 & The University of St Andrews 2018 & Heriot-Watt
University 2019)
• CCPBioSim Conference (Derby University, July 2016 & University of
Southampton, 2017)
• Joseph Black conference (The University of Edinburgh, 2017)
• Allostery RSC conference (The Royal Society, London, 2017)
• Cecam: Computational allostery (Lausanne Switzerland, 2017)
• Astbury Conversation(University of Leeds, 2018)
198 Appendix D. Presentations and posters
• Annual UCB PhD day (Royal College of Physicians London, October
2016, October 2017, October 2018)
D.1.3 Poster prizes
• 1st place poster prize:
Joseph Black Conference
(University of Edinburgh: 1st June 2017)
• 1st place poster prize:
11th ScotCHEM Computational Chemistry Symposium
(University of Glasgow: 16th June 2017)
• 1st place poster prize:
UCB PhD day
(London: 23rd October 2017)
• 3rd place poster prize:
UCB PhD day
(London: 24th September 2018)
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